

October 7, 2009

EEOICPA LIABILITIES as of SEPTEMBER 30, 2009

PURPOSE

Quality Casualty Consulting (QCC) has been retained by the US Department of Labor (DOL) to estimate liabilities of the government to pay claims under the Energy Employees Occupational Illness Compensation Program Act (EEOICPA). The liabilities are as of the end of the latest fiscal year ending 9/30/09.

This evaluation is for both Part B, which became effective July 31, 2001, and Part E which became effective October 29, 2004. The estimation is based as much as possible on actual experience under the program. It includes no estimate of administrative costs.

Although claims are projected to emerge in the future, we consider only those based on employments before 9/30/09, the as of date. There is no liability calculated for exposure to toxic substances after 9/30/09. There is also no estimate of liability that may result from future law or administrative changes. The estimate does not include any loss adjustment expenses.

CONCLUSIONS

We have estimated liabilities under Part B of the EEOICPA as of 9/30/09 to be \$4,208,726,174, discounted by an interest rate of 4.715%. On an undiscounted basis, the liability is \$6,681,514,227. These numbers are shown in Exhibit 1.

At the end of fiscal year 2008, the Part B liabilities were \$4,043,713,292 discounted by an interest rate of 4.770% and \$6,236,610,079 on an undiscounted basis. The estimate of

liabilities has increased since the end of last year primarily due to higher projected number of cancer claims particularly SEC and a slightly lower rate used to discount losses.

Liabilities under part E of the Act are estimated to be \$3,854,836,876 discounted by the rate above, and \$6,077,121,631 on an undiscounted basis.

At the end of 2008, the Part E liabilities were estimated to be \$4,055,605,311 discounted by the rate above, and \$6,829,426,204 on an undiscounted basis. The liabilities have decreased moderately primarily due to payments in 2008 and change in projected decay rate of Part E claims.

The estimate of liability is an actuarial central estimate, an estimate that represents an expected value over the range of reasonably possible outcomes. There are no recoverables for this coverage.

BACKGROUND ON THE EEOICPA

Under Part B, the act provides a lump sum "indemnity" award of \$150,000 and medical benefits to living claimants who were employed in various energy-related activities either directly for the Department of Energy (DOE), or its contractors and sub-contractors. Claimants may include the survivors of deceased workers who would have been eligible for the awards and, in that case, the lump sum is divided among eligible survivors.

Coverage is coordinated with benefits to certain uranium workers under the Radiation Exposure Compensation Act (RECA). Individuals who have received, or will receive, the \$100,000 indemnity benefit under that act are presumed eligible for a \$50,000 indemnity award under the EEOICPA to "top up" the RECA benefit. Liability for benefits has been transferred by the 2004 amendments so that RECA ground-up payments, including medical, have been assumed by the DOL under the EEOICPA.

Except for some broadening of coverage in the coordination with RECA, Part B coverage is for certain specified diseases only: cancer due to radiation exposure, and beryllium disease or silicosis related to exposure to those elements. These must be related to exposures at covered employment and exposures must satisfy certain temporal requirements. Special cases, workers with beryllium sensitivity, qualify for only certain medical benefits.

In a significant expansion of coverage to employees of contractors and subcontractors of the government, Part E was also added to the act, effective October 29, 2004. This extends federal compensation and medical benefits in lieu of state workers compensation benefits for injury and lost income of workers who developed occupational illness as a result of exposure to a broader selection of toxic substances at a DOE facility. This replaced Part D, which provided help to these workers in obtaining state benefits. Old Part D claims have been transferred to the new Part E program. Many claimants already accepted under Part B and RECA will be considered eligible for Part E benefits.

There are detailed requirements, which are only outlined below, that must be fulfilled in order to qualify for benefits under Part B. It should be noted that workers from certain specific locations are in the Special Exposure Cohort (SEC) and have been given favorable status towards acceptance. The SEC is workers at specific locations before February 1, 1992 who worked at least 250 days and have developed certain specific types of cancer.

Claimants must not be suing the government in tort nor be convicted felons. To receive awards, claimants must accept the lump sum payment in full for all claims against the US, DOE and its contractors and sub-contractors. For the purposes of this evaluation, we have assumed that all claimants will accept the EEOICPA award, dropping any lawsuits that may be pending.

THE DATA

Data that has been made available to us are extracts made to our specifications from a database constructed by the program administrators. There are several tables of data, many of which relate to details of the administration of the claims and are not relevant to our estimation. The tables with information useful in the estimation of liabilities contain key information on case (employee) and several with information by claim (which may be either the living employee or one or more of his/her survivors). Extracts requested by us include information on the employee (such as birth date, date of death, and disease), claimant (such as relationship, time of filing and payment), and claim status (relating to eligibility and possible administrative decisions to accept or deny.) We also obtained information on medical condition, claims with SEC status, and payments. These extracts were done as of July 2009. By using our model, we were able to project to an evaluation as of 9/30/09.

In addition to the above extracts, we were able to obtain information on EEOICPA medical payments by case from inception to 7/09 and RECA benefits paid on behalf of DOJ.

We do not have a count of workers by year or location that have been exposed to dangerous substances.

OVERVIEW OF THE ANALYSIS

The general approach to evaluating Part B has been to estimate ultimate case count by medical condition, or disease, and extend that by the dollar value of the indemnity award, \$150,000. The critical injury types in this case are covered cancers, beryllium disease and chronic silicosis. Beryllium sensitivity is subject to medical awards only, and these cases were separated out. RECA cases which originated from a different program were also separated out.

To best use the available experience, we have done the estimate of future compensation respective of disease. We also separated out medical payments, which will have a different payment pattern than compensation.

Using the RECA indicator field, we first separated out cases resulting from coordination with the Radiation Exposure Compensation Act (RECA), which are mostly radiation-induced cancer and other lung diseases. Prior to the October 2004 changes, these were subject to a \$50,000 award per case under EEOICPA. Since it is expected to have a different administration and acceptance rate, RECA is treated as one of the qualifying diseases and these cases are separated out first. As a result of the October 2004 changes, new RECA cases will be paid the full \$150,000 under EEOICPA.

Prior to 2007, the \$100,000 per case paid on behalf of the DOJ on RECA cases was not included in our paid data. For the last several years we have obtained data on payments on behalf of the DOJ for RECA cases from a separate data base and are able to add these amounts to the \$50,000 per case paid by the DOL to obtain the total amount paid. This year, as in the past several years, the projection of liability for RECA cases use \$150,000 per case and thus incorporates both the \$50,000 per case payable under the original Part B and the additional amounts payable on behalf on the DOJ.

We assign cases to medical condition in the following priority order: RECA, cancer SEC, beryllium disease, chronic silicosis, cancer other than SEC and beryllium sensitivity. If more than one condition appeared for any given case, we used that order to slot the case.

Using the data from our extract, we projected the pattern and ultimate number of reported Part B cases by disease using an exponential decay model. Included in this projection is the emergence pattern for cases, that is, the number of cases projected to be filed each quarter for 21 years into the future.

We did not directly model the detailed process by which these diseases are judged to qualify for an award, but, based on sample recommendation and final approval rates, we selected estimates of the approval rate for cases of each disease.

Separate files were provided for Part E claims with dates, status and payment amount, allowing overlap with Part B claims just as awards are allowed to overlap. At this point, dividing Part E cases by disease seems unnecessary. We projected future emergence of cases in much the same way as for Part B cases. We also used information on the payments to date to estimate an average Part E indemnity award. For Part E we projected cases to be filed each quarter for 36 years into the future.

Medical payments are recorded to case and for cases approved under both Part E and Part B, the medical payments cannot be distinguished. We used a similar method to that of the DOL for allocating medical payments to Part B and Part E. Medical is counted as Part E only if there is no Part B claim or if the Part B claim is denied and the Part E claim is approved. Medical data is presented in Exhibit 2.

This year there was a problem with the medical data originally received from DOL. The putative payments in fourth quarter 2007 were extremely high and the payments in second quarter 2009 were very low. We talked to DOL and obtained a new medical data extract as

of September 2009. In comparing the two files, we noticed that amounts in the original file with paid dates of 12/13/2007 and 12/20/2007 now appear as amounts with paid dates in second quarter 2009. The total amount paid from the original file was reasonable compared to statistics on EEOIC on the web site, as well as compared to the new file. Since we only use the totals and a general idea of the trend, we did not revise all the exhibits.

We projected the annual medical benefit paid under Part B to be \$9,540 for 2010, 6% higher than the selected Part B medical benefit for 2009 used last year. For Part E we selected \$3,800. The selected escalation rate is 6%, the same as last year. There is a difference in presentation from last year. Last year both Part B and Part E annual medical benefit were selected the same, \$9,000, but a factor of 40% was applied to Part E medical to account for cases where the Part B claim was approved and medical is paid under Part B. The medical annual payment selected this year for Part E is approximately 40% of the Part B annual payment.

For Part B, we estimated quarterly average medical benefit per living employee with an approved case. This average medical benefit is taken over a broader base of employees and is thus smaller than the average medical amount paid to claimants actually receiving benefits. We calculated averages for Part B in total and for each of the larger disease categories: RECA, cancer SEC and cancer non-SEC. We also calculated an average medical for beryllium disease, chronic silicosis, and beryllium sensitivity combined. The average annual benefit is four times the quarterly.

We also projected the numbers of eligible employee claimants living during each future quarter who could receive ongoing medical benefits. The product of the average medical benefit and the number of eligible employees is the projected medical benefit.

After projecting the number of claims that will be filed and approved, we estimate how long after the claims are filed that they are paid to determine the compensation payment pattern. The number of claims paid times the average benefit is the amount paid.

DETAILED METHODOLOGY

Since the full award inures to the case, not the claim, we consolidated the data to a case basis. We segregated cases by disease using claim data, and we prioritized diseases so that cases coded to multiple diseases could be assigned to one disease.

A. Construction of database

For Parts B and E combined:

From the case (.cas) table, we extracted date of birth, date of death, and sex.

Medical amounts paid by case were provided in a table of medical benefits.

For each Part, B and E separately:

From the claim (.claim) table, we determined the case number, the date filed (earliest claim filed), if the claim was for employee, survivors or both, and if the claim was RECA.

From the medical condition table (.med_condition), we determined the disease using the primary medical condition code. We used a priority order if there was more than one disease listed. The priority was as follows: RECA, cancer SEC, beryllium disease, chronic silicosis, cancer non SEC, beryllium sensitivity, other lung, renal, other, 99 (Other Conditions, Not Listed) and blank. This was used to stratify the cases.

From the claim status table (.claim_status_history), we determined an approval status of each case. We recorded if Final Adjudication Branch (FAB) affirmed or denied an underlying claim, if approval was recommended or denied by the district administrators, or if it were closed. By assumption, approval of one underlying claim inured to the case.

Paid dates and amounts were taken from the payment (.payment) table. From claim payment data we received, we combine amounts paid by claim to case for each full quarter up to the one ending 6/08.

For Part B only:

If a claim is indicated as SEC in the SEC table (.emp_sec) or has an “SE” in the status history table (.claim_status_history), the claim was classified as SEC. If any underlying claim was SEC, then the case was so coded as SEC in our database.

This year, as last year, we have obtained all amounts paid by the DOL on behalf of the DOJ for RECA claims. This is \$100,000 per RECA claim. These amounts are summarized by date paid and added to the \$50,000 per claim paid on RECA claims in the database.

For Part E only:

From the acceptance of payment table, the breakdown of payment by lump sum, wage loss, and impairment was determined.

B. Estimating an emergence pattern of paid cases, respective of disease

1. Estimate the ultimate number of reported cases and an emergence pattern by disease.

Using this model, we estimate ultimate number of reported cases, as well as a pattern of reporting.

We start with the reported case count as of the latest full evaluation, 6/30/09. Using case counts reported by quarter, we determine a reporting pattern. Using an exponential decay model we determine how many cases are expected to be filed (in a statistical sense) in each of the upcoming quarters. Projections based on the fitted exponential decay model imply few cases will be filed after 2030 for Part B and after 2045 for Part E. We limit the number of years in our case projection exhibits to 21 for Part B and 36 for Part E, not including the 8 completed years. Medical payments are projected out over 50 years. Beyond this time there will undoubtedly be payments, but far fewer and highly discounted for interest. Most of the cases involve workers in their sixties, so these time frames are not unreasonable.

Before fitting the exponential model, some judgment was necessary to adjust quarters with an apparent excess of reported cases, typically the first quarter of the program, which was the third quarter of 2001. There presumably was a backlog of cases brought out by the new program. We excluded this quarter. We also judgmentally adjusted the fitted parameters to be reasonable and consistent with each other across diseases.

2. Estimate the number of reported cases that will be approved and paid. This we have done using approval rate statistics by disease that we derived from the status history table, so that a sample rate of approval is the number of approved cases divided by the total (approved + disapproved). We look at approval rates based on both the divisional recommendations and the Final Adjudication Branch (FAB) but since there is enough history on approval rates, we generally select an approval rate based on the FAB approval rate.

C. Estimating a payment pattern

1. We start with the emergence pattern estimated as described in Section B.1 above. We assumed Part B cases other than CN-NONSEC are paid one year after they are reported with a three year lag for CN-NONSEC cases. For Part E we assume a one year lag from filing to approval and two year duration of payments. For some diseases, the payout assumptions lead to a large number of cases to be paid in the year following the estimate. To avoid this lump of cases, we spread the difference uniformly between the estimated approved cases and the number paid to date over five years for RECA, CN-SEC, BD, and CN-NONSEC cases. For Part E the correction term is spread over 10 years.
2. Compensation payment amounts are \$150,000 for part B cases. (RECA payments, which were once only \$50,000, are now also projected at \$150,000). For Part E, we estimated an average award of \$143,000 using analysis described in Exhibit 3, page 5.

3. Medical payment amounts are derived by estimating an average benefit award per eligible employee and a projection of how many such employee claimants are living in each year after the current. We selected \$9,540 for Part B and \$3,800 for Part E as the average amount paid in 2010. The Part B selection is higher than the current indication for Part B but we expect a higher percentage of future claims to be CN-SEC which has higher than average medical costs. For projecting future medical payments, we retained our estimate of medical inflation at 6%.
4. To project living employee claimants, those eligible for medical benefits, we used mortality rates for existing disabled male retirees from the RP-2000 Mortality Tables published by the Society of Actuaries, as well as our model estimate of new claimants emerging.

DESCRIPTION OF EXHIBITS

Exhibit 1, page 1 - The Estimate of EEOICPA Liabilities.

Usually liability is computed as the ultimate incurred minus paid loss to date, where loss is compensation plus medical. In this case, we used our model of the payment stream by disease and directly summed payments starting 10/01/09. We also calculate discounted liabilities using our payment pattern from Exhibit 6 and an interest rate of 4.715%.

Exhibit 1, page 2- Assumptions used in the calculations

The assumptions are for discount rate, approval rate, portion of cases filed by living employee, mortality rates, medical cost and inflation rates.

Exhibit 2 - Summary Medical Paid Loss Data

Averages are taken over several different disease groups.

Exhibit 3 - Summarized Information from our Data Base

Tables 1 through 12 show summarized information from the database.

From this data, we estimated a case approval rate and payments made by disease and year. The approval of a case required only that one underlying claim be approved, and we did not count a case as disapproved if any underlying claim was approved or reopened.

Exhibit 3, page 5 – Estimate of Part E average compensation award

The various possible types of cases and claimants are weighted to produce a single average award. Because of possible overlap in the categories, the weights used in the selection total to more than 100%.

Exhibit 4 - Estimation of Ultimate Case Count and Emergence Pattern by Disease

To calculate the ultimate number of cases reported by disease, we projected based on reported case counts from the latest 31 quarters in our database. This excluded the third quarter of 2001. We fit an exponential decay reporting pattern to the quarterly data. Using actual cases as of 6/30/09, the last complete quarter, and the fitted pattern for projection, we were able to calculate an expected ultimate number of reported cases. We selected exponential parameters that may have differed from the values resulting from the fit on the existing data usually by comparing last years projections for the current year to the actual number of claims filed and by comparing future projection with the latest reported numbers.

In addition to an estimate of an ultimate number of cases, the exponential decay model also gives us a reporting pattern, which we have used to derive a payment pattern for discounting.

Exhibit 5, page 1 - Estimated Ultimate Approved Cases by Disease

Using the selected approval rate by disease from Exhibit 1 and the number of filed claims from Exhibit 4, we calculated the expected number of cases reported by fiscal year that would be approved.

Exhibit 5, page 2 - Estimated Ultimate Paid Cases by Disease

The database gives us information about the difference between the filing date and the approval date. For all Part B diseases except CN-NONSEC, we assumed payout would follow the year after the (approved) case was filed. For CN-NONSEC we assumed payout three years after filing. Part E cases are assumed to be paid 3 years after filing which represents 1 year from filing to approval and a two year duration of payments. This assumes that cases will be decided more quickly now that most of the initial backlog of claims has been handled. Further adjustments are made as described in the exhibit and in section C1 of this report.

Exhibit 5, page 3 – Cases Eligible for Medical Expenses

To be eligible for medical, claims must be approved and filed by a living employee. Once he/she becomes eligible, the claimant continues to be eligible in subsequent years, subject to mortality.

Exhibit 6 - Dollars Paid by Disease by Fiscal Year

The liability by disease is the sum of projected payments after 9/30/09, and summarized on Exhibit 1.

The projected payout of cases is used in conjunction with actual payments to date to derive the payout distribution by fiscal year, which can be used with a selected interest rate to

discount the liabilities. The interest rates decreased a little this year compared to last year so the discounted liabilities are somewhat higher than if last years interest rate was used.

Exhibit 7 – Sensitivity Analysis

By far the most sensitive part of our analysis is the projection of ultimate emerged cases. This is especially difficult because we don't really know the true exposure to loss, which is the number of at-risk employees. Though there have been some estimates in total and maybe by occupation, what we would really like is number of employees by year of employment. As far as we know, this is not available.

Our other selections have less overall impact, but correlation of these is possible and the consequent error in our projection of these could still be quite large. Exhibit 7 shows estimates of liability with some different parameter selections to provide an idea of how much the estimate could vary if different parameters were selected.

1. An exponential decay model is reasonable if there are no exogenous factors, but with existing changes in administration such as awareness programs and the addition of new SEC classes, we see actual changes that cannot fully be modeled. For sensitivity, we tested the impact of increasing and decreasing the selected slope parameter one percentage point, 0.01. This sounds like a small change but the slope parameters are in the range .02 to .09 so .01 is a large percentage change. The increase in slope increased discounted reserves some 47%, while the decrease reduced them 24%. The model is especially sensitive to this selection.
2. The choice of Medical inflation rate can also have great impact. Our selection of 6% is higher than that selected by the Office of Management and Budget (OMB) for projecting FECA medical payments in the DOL model, but is certainly reasonable. Our tests show the impact of varying this assumption is that an 8% rate would increase discounted total reserve 10.5% and a 4% rate would reduce discounted total reserves 7.5%.
3. Change in Medical cost per case has a lesser impact on reserves so that a 10% increase in the cost per case increases total reserves only 3.8% while a 10% decrease in that cost reduces reserves by the same percentage. Our choice of medical average cost has moderate impact.
4. Approval rates have a slightly leveraged impact, so that a 10% higher approval rate increases the reserve over 16% while a 10% lower approval rate tends to reduce reserves 17%. The approval rates have become more stable for all diseases except possibly Part E. Re-adjudication of previously denied claims has increased the uncertainty of the long term approval rate.
5. Interest rates can have great impact. We used the OMB's recommendations for long term interest rates used in the FECA reserves and see little need for judgmental

adjustment. We show a one point change in interest rate can impact reserves about 7-9%.

CHANGES IN METHODOLOGY

The major changes in methodology compared to last years analysis:

- 1) Rather than a factor applied to Part E medical we selected distinct medical costs per case for Part E and Part B. This is actually a presentation change rather than a methodology change.
- 2) We adjusted the assumptions as to how long it takes to pay a claim. CN-NONSEC cases are assumed to be paid three years after filing instead of two. BD, CS are assumed to be paid one year after filing instead of two. Part E claims are assumed to be paid 3 years after filing instead of 4. These changes were made because it appears generally that most claims are being paid faster now that the backlog is clearing. Claims that go to NIOSH still require a significant time to settle, which may explain why CN-NONSEC claims take longer to settle..
- 3) The selected approval rates and decay rates for some diseases are changed based on the new data. Of most significance, Part E approval rate is increased from 40% to 44%, the decay rates for cancer claims, CN-SEC and CN-NONSEC are decreased and the decay rate for Part E is increased.

CAVEATS

This work is a good faith estimate of the EEOICPA liabilities. We have tried to use the actual experience as much as possible to make our estimate and also give weight to information from staff about changes in the program that are not yet seen in the data. Nevertheless, the estimate is based to a great extent on judgment. As with all such estimations of future contingent events, this one, even based on known experience, includes a significant probability of being incorrect. This risk is contained in all actuarial estimations of future costs, but is particularly high in this case.

The EEOICPA program is relatively new, with only a short history to serve as an example of possible events especially when compared to a commercial line of insurance such as Workers Compensation or Premises Liability. The EEOICPA experience so far is only a fraction of the ultimate events that will occur as this program plays out. Part E in particular has generated very little experience so we are relying heavily on judgment to produce estimates.

We relied on the data supplied by the Department of Labor to make this estimate. We examined it for consistency and reasonableness but otherwise relied on the accuracy of the information provided to us.

What actuaries call the exposure to loss - the time, place, people and what they were doing many years ago - is not measured very accurately in comparison to commercial insurance lines of business, where we would have audited payroll by year and location, and comparatively prompt notification of insured events. In this case, eligible claimants were working at several different locations during many different time periods spanning many years in the past.

Qualification for the benefits is based on a newly instituted and evolving administrative procedure, again with not much historical experience to model the process. One constant has been that for Part B, the size of the awards: a flat lump sum of \$150,000. This helps reduce possible error in the estimate. For Part E there are varying possible awards adding another source of error in the estimate.

There are three possible kinds of risk in all estimations. One is parameter risk, or the risk that our model of the process is not accurate. There are many variables that impact the results and it is possible that some of them are not estimated accurately. The parameter risk in this case is sizable.

Another is called process risk. Even if we are able to correctly model the loss process, it is, after all, stochastic, and actual events may depart from what we predict, even if what we predict is correct on average. Actuaries would call this average the true expected losses. Because the possible triggers for an award under the EEOICPA are so complex, process risk is high, and fortuitous events in the future may not follow patterns seen in the data.

The third is model risk. This is the risk that the model is not appropriate for the estimate. For example, the exponential decay model for modeling the number of claims may not be appropriate for this particular coverage.



Judy A. Gillam, FCAS, MAAA



William R. Gillam, FCAS, MAAA

**ESTIMATED LIABILITY FOR EEOIC
AS OF 9/30/2009**

Undiscounted Future Liability	Part B \$6,681,514,227	Part E \$6,077,121,631	Total \$12,758,635,858
Discounted Liability Using an interest rate of 4.715%	\$4,208,726,174	\$3,854,836,876	\$8,063,563,050

ESTIMATED PAYOUT FOR CURRENT EEOIC LIABILITY

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Fiscal Year	Years of Discount	Discount Factor	PART B Undiscounted Payout	= (3) x (4) PART B Discounted Payout	PART E Undiscounted Payout	=(3) x (6) PART E Discounted Payout
10/09-9/10	0.5	0.977	469,671,900	458,869,446	486,442,600	475,254,420
10/10-9/11	1.5	0.933	420,508,704	392,334,621	412,464,836	384,829,692
10/11-9/12	2.5	0.891	405,038,517	360,889,319	385,842,310	343,785,498
10/12-9/13	3.5	0.851	385,650,856	328,188,878	357,863,820	304,542,111
10/13-9/14	4.5	0.813	368,597,060	299,669,410	332,365,579	270,213,216
10/14-9/15	5.5	0.776	301,823,596	234,215,110	310,228,565	240,737,366
10/15-9/16	6.5	0.741	286,343,838	212,180,784	290,852,870	215,521,977
10/16-9/17	7.5	0.708	272,512,090	192,938,560	273,536,012	193,663,496
10/17-9/18	8.5	0.676	260,704,165	176,236,016	258,701,774	174,882,399
10/18-9/19	9.5	0.646	249,734,424	161,328,438	245,036,720	158,293,721
10/19-9/20	10.5	0.616	239,064,000	147,263,424	188,500,025	116,116,015
10/20-9/21	11.5	0.589	228,150,100	134,380,409	176,859,402	104,170,188
10/21-9/22	12.5	0.562	218,369,144	122,723,459	165,755,640	93,154,670
10/22-9/23	13.5	0.537	209,037,812	112,253,305	155,807,340	83,668,542
10/23-9/24	14.5	0.513	199,823,963	102,509,693	146,445,387	75,126,484
10/24-9/25	15.5	0.490	191,570,535	93,869,562	137,846,972	67,545,016
10/25-9/26	16.5	0.468	183,033,565	85,659,708	129,727,696	60,712,562
10/26-9/27	17.5	0.447	174,515,670	78,008,504	121,999,009	54,533,557
10/27-9/28	18.5	0.426	166,085,230	70,752,308	114,824,996	48,915,448
After 9/28			1,451,279,058	444,455,220	1,386,020,078	389,170,498
TOTAL			\$6,681,514,227	\$4,208,726,174	\$6,077,121,631	\$3,854,836,876

Column (4) payout is from Exhibit 6 column (9) excluding amounts paid before 9/30/09

Column (6) payout is from Exhibit 6 column (12) excluding amounts paid before 9/30/09

Column (3) is 1 divided by 1 plus the interest rate selected for discounting, raised to the power in column (2)

Inputs for Estimation of EEOIC liabilities

Exhibit 1
Page 2

Table 1

Interest Rate to use for Discounting Reserves 4.715%

Table 2

Selected rate of approval of filed claims Actual data is in Exhibit 3 Page 2 Tables 5 and 6.

RECA	95%
BD	53%
CS	18%
CN - SEC	77%
CN - NONSEC	26%
BS	57%
PART E	44%

Table 3

Selected percentage of Cases Filed by Living Employee. These cases are eligible for medical benefits.
Actual data is in Exhibit 3 Page 1 Table 2.

RECA	54%
BD	58%
CS	72%
CN - SEC	48%
CN - NONSEC	56%
BS	99%
PART E	60%

Table 4

Mortality Rates
Assumed Average Age at Filing Claim is 67

(1)	(2)	(3)
Age	Mortality Rate	= 1-(2)
67	0.054450	0.9456
68	0.056909	0.9431
69	0.059613	0.9404
70	0.062583	0.9374
71	0.065841	0.9342
72	0.069405	0.9306
73	0.073292	0.9267
74	0.077512	0.9225
75	0.082067	0.9179
76	0.086951	0.9130
77	0.092149	0.9079
78	0.097640	0.9024
79	0.103392	0.8966
80	0.109372	0.8906
81	0.115544	0.8845
82	0.121877	0.8781
83	0.128343	0.8717
84	0.134923	0.8651
85	0.141603	0.8584
86	0.148374	0.8516
87	0.155235	0.8448
88	0.162186	0.8378
89	0.169233	0.8308
90	0.183408	0.8166
91	0.199769	0.8002
92	0.216605	0.7834
93	0.233662	0.7663
94	0.250693	0.7493
95	0.267491	0.7325
96	0.283905	0.7161
97	0.299852	0.7001
98	0.315296	0.6847
99	0.330207	0.6698
100	0.344556	0.6554
101	0.358628	0.6414
102	0.371685	0.6283

Column (2) Mortality Rates are from Male RP-2000 Rates for Disabled Retiree

Table 5

Selected Part B Medical Annual Cost \$9,540
Selected Part E Medical Annual Cost \$3,800
Medical Inflation Rate = 6%

(1)	(2)	(3)		
Fiscal Year		Avg. Medical		
Ending		Benefit	Part B	Part E
9/10	1	9,540		\$3,800
9/11	2	10,112		4,028
9/12	3	10,719		4,270
9/13	4	11,362		4,526
9/14	5	12,044		4,797
9/15	6	12,767		5,085
9/16	7	13,533		5,390
9/17	8	14,345		5,714
9/18	9	15,205		6,057
9/19	10	16,118		6,420
9/20	11	17,085		6,805
9/21	12	18,110		7,214

Column (3) is the medical annual cost times 1 plus the medical inflation rate raised to the power in column (2) - 1
Actual data from Exhibit 2 Table 1.

ESTIMATE OF PAID MEDICAL FOR EEOIC

Exhibit 2
Page 1

Table 1

ALL PARTS B AND E

Actual Medical Paid Quarterly Per all Eligible Cases

	(1)	(2)	(3)	(4)	(5)
	Cases Eligible	Cumulative	Total Medical Paid	Total Medical Paid	= (4) / (3) Average
3Q 2001	50	50	-1,359,487	-1,359,487	-27,190
4Q 2001	404	454	2,153	2,153	5
1Q 2002	374	828	302,794	302,794	366
2Q 2002	383	1,211	1,537,000	1,537,000	1,269
3Q 2002	407	1,618	1,980,454	1,980,454	1,224
4Q 2002	457	2,075	1,743,499	1,743,499	840
1Q 2003	388	2,463	3,437,996	3,437,996	1,396
2Q 2003	244	2,707	4,334,275	4,334,275	1,601
3Q 2003	177	2,884	5,223,288	5,223,288	1,811
4Q 2003	208	3,092	4,178,941	4,178,941	1,352
1Q 2004	246	3,338	7,171,777	7,171,777	2,149
2Q 2004	216	3,554	6,443,989	6,443,989	1,813
3Q 2004	222	3,776	5,207,840	5,207,840	1,379
4Q 2004	211	3,987	6,833,070	6,833,070	1,714
1Q 2005	249	4,236	7,931,955	7,931,955	1,873
2Q 2005	306	4,542	9,065,376	9,065,376	1,996
3Q 2005	317	4,859	8,947,440	8,947,440	1,841
4Q 2005	303	5,162	7,855,636	7,855,636	1,522
1Q 2006	374	5,536	11,330,589	11,330,589	2,047
2Q 2006	415	5,951	12,171,679	12,171,679	2,045
3Q 2006	486	6,437	10,275,928	10,275,928	1,596
4Q 2006	461	6,898	9,403,769	9,403,769	1,363
1Q 2007	624	7,522	13,410,427	13,410,427	1,783
2Q 2007	930	8,452	17,336,369	17,336,369	2,051
3Q 2007	1,092	9,544	20,345,258	20,345,258	2,132
4Q 2007	981	10,525	32,426,159	32,426,159	3,081
1Q 2008	887	11,412	17,806,320	17,806,320	1,560
2Q 2008	1,061	12,473	19,529,486	19,529,486	1,566
3Q 2008	1,222	13,695	23,313,996	23,313,996	1,702
4Q 2008	1,178	14,873	26,900,012	26,900,012	1,809
1Q 2009	979	15,852	26,209,149	26,209,149	1,653
2Q 2009	1,083	16,935	15,181,449	15,181,449	896
Total	16,935	196,941	336,478,585	336,478,585	1,709

There is a problem with the medical data by quarter, namely that amounts with paid dates of 12/13/2007 and 12/20/2007 should show paid dates in second quarter 2009. This was determined from a new file of medical data provided by DOL. Since the totals are correct and our selections of medical quarterly payments are not affected, the exhibits were not revised for the new data.

ESTIMATE OF PAID MEDICAL FOR EEOIC

ALL PART B

Actual Medical Paid Quarterly Per all Eligible Cases

Exhibit 2
Page 2

	(1)	(2)	(3)	(4)	(5)
		Cases Eligible	Cumulative	Total Medical Paid	= (4) / (3) Average
3Q 2001		50	50	-1,289,764	-25,795
4Q 2001		404	454	2,153	5
1Q 2002		374	828	302,794	366
2Q 2002		383	1,211	1,537,000	1,269
3Q 2002		407	1,618	1,980,379	1,224
4Q 2002		457	2,075	1,743,108	840
1Q 2003		388	2,463	3,431,229	1,393
2Q 2003		244	2,707	4,326,868	1,598
3Q 2003		177	2,884	5,214,066	1,808
4Q 2003		208	3,092	4,171,814	1,349
1Q 2004		246	3,338	7,160,515	2,145
2Q 2004		216	3,554	6,424,221	1,808
3Q 2004		222	3,776	5,185,806	1,373
4Q 2004		211	3,987	6,824,268	1,712
1Q 2005		249	4,236	7,911,125	1,868
2Q 2005		306	4,542	9,022,578	1,986
3Q 2005		315	4,857	8,842,301	1,821
4Q 2005		296	5,153	7,691,419	1,493
1Q 2006		359	5,512	10,647,940	1,932
2Q 2006		380	5,892	11,513,923	1,954
3Q 2006		422	6,314	9,461,669	1,499
4Q 2006		352	6,666	8,482,169	1,272
1Q 2007		422	7,088	12,158,684	1,715
2Q 2007		540	7,628	15,994,352	2,097
3Q 2007		512	8,140	18,757,561	2,304
4Q 2007		409	8,549	28,711,931	3,359
1Q 2008		389	8,938	16,165,690	1,809
2Q 2008		337	9,275	17,599,490	1,898
3Q 2008		441	9,716	19,826,304	2,041
4Q 2008		421	10,137	23,035,395	2,272
1Q 2009		296	10,433	22,236,790	2,131
2Q 2009		300	10,733	12,129,715	1,130
Total		10,733	165,846	307,203,490	1,852

ESTIMATE OF PAID MEDICAL FOR EEOIC

PART B RECA

Actual Medical Paid Quarterly Per all Eligible Cases

Exhibit 2
Page 3

	(1)	(2)	(3)	(4)	(5)
		Cases Eligible	Cumulative	Total Medical Paid	= (4) / (3) Average
3Q 2001		37	37	-230,230	-6,222
4Q 2001		290	327	800	2
1Q 2002		108	435	82,905	191
2Q 2002		82	517	85,981	166
3Q 2002		109	626	186,475	298
4Q 2002		100	726	201,816	278
1Q 2003		82	808	391,191	484
2Q 2003		50	858	729,448	850
3Q 2003		41	899	1,092,352	1,215
4Q 2003		62	961	937,513	976
1Q 2004		79	1,040	1,249,458	1,201
2Q 2004		83	1,123	1,256,372	1,119
3Q 2004		79	1,202	1,250,506	1,040
4Q 2004		51	1,253	2,798,399	2,233
1Q 2005		110	1,363	3,918,187	2,875
2Q 2005		122	1,485	4,207,671	2,833
3Q 2005		97	1,582	3,691,239	2,333
4Q 2005		81	1,663	2,420,970	1,456
1Q 2006		92	1,755	5,134,562	2,926
2Q 2006		65	1,820	4,997,519	2,746
3Q 2006		105	1,925	3,692,906	1,918
4Q 2006		78	2,003	3,067,159	1,531
1Q 2007		155	2,158	4,547,307	2,107
2Q 2007		257	2,415	6,701,169	2,775
3Q 2007		237	2,652	6,630,057	2,500
4Q 2007		142	2,794	10,457,107	3,743
1Q 2008		112	2,906	5,825,866	2,005
2Q 2008		67	2,973	6,492,837	2,184
3Q 2008		102	3,075	6,734,903	2,190
4Q 2008		80	3,155	8,750,907	2,774
1Q 2009		74	3,229	8,081,153	2,503
2Q 2009		52	3,281	3,808,843	1,161
Total		3,281	53,046	109,193,350	2,058

ESTIMATE OF PAID MEDICAL FOR EEOIC

PART B CN-SEC

Actual Medical Paid Quarterly Per all Eligible Cases

Exhibit 2
Page 4

(1)	(2)	(3)	(4)	(5)
	Cases Eligible	Cumulative	Total Medical Paid	= (4) / (3) Average
3Q 2001	13	13	-553,902	-42,608
4Q 2001	83	96	1,354	14
1Q 2002	177	273	217,818	798
2Q 2002	115	388	1,415,875	3,649
3Q 2002	131	519	1,644,930	3,169
4Q 2002	103	622	1,272,103	2,045
1Q 2003	100	722	2,020,038	2,798
2Q 2003	86	808	2,288,713	2,833
3Q 2003	44	852	3,084,031	3,620
4Q 2003	53	905	2,531,516	2,797
1Q 2004	52	957	4,486,358	4,688
2Q 2004	44	1,001	3,997,496	3,994
3Q 2004	50	1,051	2,975,627	2,831
4Q 2004	57	1,108	2,892,098	2,610
1Q 2005	38	1,146	3,038,001	2,651
2Q 2005	55	1,201	3,310,522	2,756
3Q 2005	77	1,278	3,379,561	2,644
4Q 2005	103	1,381	3,595,667	2,604
1Q 2006	101	1,482	3,895,692	2,629
2Q 2006	108	1,590	3,980,363	2,503
3Q 2006	113	1,703	3,606,309	2,118
4Q 2006	88	1,791	3,358,779	1,875
1Q 2007	93	1,884	4,846,738	2,573
2Q 2007	95	1,979	6,159,044	3,112
3Q 2007	126	2,105	8,114,108	3,855
4Q 2007	155	2,260	12,381,504	5,479
1Q 2008	147	2,407	6,684,999	2,777
2Q 2008	132	2,539	6,888,016	2,713
3Q 2008	194	2,733	8,045,711	2,944
4Q 2008	211	2,944	9,470,257	3,217
1Q 2009	129	3,073	8,419,718	2,740
2Q 2009	144	3,217	4,852,298	1,508
Total	3,217	46,028	132,301,341	2,874

ESTIMATE OF PAID MEDICAL FOR EEOIC

PART B CN-NONSEC

Actual Medical Paid Quarterly Per all Eligible Cases

Exhibit 2
Page 5

(1)	(2)	(3)	(4)	(5)
	Cases Eligible	Cumulative	Total Medical Paid	= (4) / (3) Average
3Q 2001	0	0	-101,910	
4Q 2001	0	0	0	
1Q 2002	0	0	0	
2Q 2002	0	0	0	
3Q 2002	0	0	1,297	
4Q 2002	2	2	3,694	1,847
1Q 2003	0	2	29,431	14,715
2Q 2003	8	10	21,720	2,172
3Q 2003	13	23	35,344	1,537
4Q 2003	41	64	51,597	806
1Q 2004	37	101	169,658	1,680
2Q 2004	29	130	125,188	963
3Q 2004	33	163	210,135	1,289
4Q 2004	61	224	273,744	1,222
1Q 2005	57	281	273,938	975
2Q 2005	79	360	443,974	1,233
3Q 2005	103	463	581,264	1,255
4Q 2005	78	541	598,923	1,107
1Q 2006	130	671	654,864	976
2Q 2006	153	824	1,485,979	1,803
3Q 2006	158	982	975,085	993
4Q 2006	140	1,122	999,405	891
1Q 2007	116	1,238	1,624,787	1,312
2Q 2007	122	1,360	1,874,649	1,378
3Q 2007	72	1,432	2,495,018	1,742
4Q 2007	47	1,479	3,406,657	2,303
1Q 2008	69	1,548	1,865,574	1,205
2Q 2008	76	1,624	2,089,742	1,287
3Q 2008	84	1,708	3,346,606	1,959
4Q 2008	63	1,771	3,091,971	1,746
1Q 2009	50	1,821	3,352,695	1,841
2Q 2009	59	1,880	2,190,744	1,165
Total	1,880	21,824	32,171,774	1,474

ESTIMATE OF PAID MEDICAL FOR EEOIC

PART B BD, CS, AND BS

Actual Medical Paid Quarterly Per all Eligible Cases

Exhibit 2
Page 6

	(1)	(2)	(3)	(4)	(5)
		Cases Eligible	Cumulative	Total Medical Paid	= (4) / (3) Average
3Q 2001		0	0	-403,723	
4Q 2001		31	31	0	0
1Q 2002		89	120	2,070	17
2Q 2002		186	306	35,144	115
3Q 2002		167	473	147,678	312
4Q 2002		252	725	265,495	366
1Q 2003		206	931	990,209	1,064
2Q 2003		100	1,031	1,286,237	1,248
3Q 2003		79	1,110	1,001,889	903
4Q 2003		52	1,162	651,187	560
1Q 2004		78	1,240	1,255,041	1,012
2Q 2004		60	1,300	1,044,566	804
3Q 2004		60	1,360	748,909	551
4Q 2004		42	1,402	859,826	613
1Q 2005		44	1,446	680,998	471
2Q 2005		50	1,496	1,059,840	708
3Q 2005		38	1,534	1,189,837	776
4Q 2005		34	1,568	1,075,859	686
1Q 2006		36	1,604	962,426	600
2Q 2006		54	1,658	1,048,243	632
3Q 2006		46	1,704	1,186,027	696
4Q 2006		46	1,750	1,053,225	602
1Q 2007		58	1,808	1,133,453	627
2Q 2007		66	1,874	1,249,706	667
3Q 2007		77	1,951	1,508,116	773
4Q 2007		65	2,016	2,437,041	1,209
1Q 2008		61	2,077	1,782,219	858
2Q 2008		62	2,139	2,117,516	990
3Q 2008		61	2,200	1,683,873	765
4Q 2008		67	2,267	1,698,672	749
1Q 2009		43	2,310	2,367,054	1,025
2Q 2009		45	2,355	1,266,887	538
Total		2,355	44,948	33,385,518	743

ESTIMATE OF PAID MEDICAL FOR EEOIC

Exhibit 2
Page 7

PART E

Actual Medical Paid Quarterly Per all Eligible Cases

(1)	(2)	(3)	(4)	(5)
	Cases Eligible	Cumulative	Total Medical Paid	= (4) / (3) Average
2Q 2005 & Prior	0	0	86,762	
3Q 2005	2	2	105,139	52,569
4Q 2005	7	9	164,217	18,246
1Q 2006	15	24	682,649	28,444
2Q 2006	35	59	657,755	11,148
3Q 2006	64	123	814,259	6,620
4Q 2006	109	232	921,600	3,972
1Q 2007	202	434	1,251,742	2,884
2Q 2007	390	824	1,342,017	1,629
3Q 2007	580	1,404	1,587,697	1,131
4Q 2007	572	1,976	3,714,228	1,880
1Q 2008	498	2,474	1,640,630	663
2Q 2008	724	3,198	1,929,996	604
3Q 2008	781	3,979	3,487,692	877
4Q 2008	757	4,736	3,864,617	816
1Q 2009	683	5,419	3,972,359	733
2Q 2009	783	6,202	3,051,734	492
Total	6,202	31,095	29,275,095	941

Column (2) is from Exhibit 3 Page 3 Table 10

Column (3) is the cumulative sum of column (2)

Column (4) is the total medical from Exhibit 3 Table 11

Eligible cases for medical are all cases with a living employee whether they have received medical benefits or not.

Selected Medical Benefit

PART B

Selected Quarterly Payment \$2,385
Selected Annual Payment \$9,540

PART E

Selected Quarterly Payment \$950
Selected Annual Payment \$3,800

Part B selection is based on RECA,CN-SEC, and CN-NONSEC

DATABASE SUMMARY INFORMATION
As of approximately 7/27/2009

Exhibit 3
Page 1

Table 1

Number of Cases and Claims By Disease

	# Cases	# Claims
RECA	7,010	11,292
BD	4,123	6,257
CS	548	763
CN-SEC	17,540	30,623
CN-NONSEC	26,226	37,802
BS	2,198	2,215
OL	3,060	3,539
RN	463	571
OTHER	4,440	4,904
99	1,327	1,420
PA	1	1
Unknown	307	330
PART B SUBTOTAL	67,243	99,717
PART E - WITH PART B CLAIM	51,562	74,579
PART E - ONLY	6,520	7,258
PART E SUBTOTAL	58,082	81,837
Cases with no Claims	401	0
TOTAL	125,726 *	181,554

*Total number of cases includes cases double counted as Part B and Part E. The total number of cases is 74,164.

Table 2

Cases Filed by Employee or Survivors or Both.

	(1) EMP	(2) SUR	(3) BOTH	(4) Percentage EMP
RECA	3,608	3,203	199	54.3%
BD	2,142	1,724	257	58.2%
CS	354	154	40	71.9%
CN-SEC	6,601	9,209	1,730	47.5%
CN-NONSEC	12,591	11,673	1,962	55.5%
BS	2,164	28	6	98.7%
PART E	31,381	23,302	3,399	59.9%
TOTAL	58,841	49,293	7,593	57.4%

Column (4) is the sum of Columns (1) and (3) divided by sum of columns (1), (2) and (3).

Table 3

Avg. Age of Employee At Time Claim is Filed

Employee Filed Cases Only

Year of Claim Filing	Part B	Number		Number	
		Cases	Part E	Cases	
2001	67	8,793	65	2,555	
2002	65	7,873	65	5,229	
2003	65	4,890	64	4,630	
2004	67	3,946	67	3,335	
2005	67	3,428	68	5,903	
2006	67	2,831	67	4,006	
2007	68	3,163	67	4,003	
2008	68	2,545	67	3,283	
2009 *	68	1,350	66	1,832	
Total	67	38,819	66	34,776	

* 2009 data is for a partial year

Table 4

Sex of Employee

	Male	Female	Blank	Male Percentage
RECA	6,880	116	14	98.3%
BD	3,661	461	1	88.8%
CS	527	20	1	96.3%
CN-SEC	15,232	2,291	17	86.9%
CN-NONSEC	23,158	3,044	24	88.4%
BS	1,764	433	1	80.3%
PART E	50,586	7,152	344	87.6%
Total	101,808	13,517	402	88.3%

Table 5

Percentage of Cases Recommended Accept

	Recommend Accept	Recommend Deny	Percentage Rec Accept
RECA	6,411	402	94.1%
BD	1,915	2,012	48.8%
CS	78	431	15.3%
CN-SEC	10,683	4,337	71.1%
CN-NONSEC	5,262	16,251	24.5%
BS	1,191	948	55.7%
OL	1	2,976	0.0%
RN	1	454	0.2%
OTHER	0	4,353	0.0%
99	2	1,304	0.2%
Unknown	0	141	0.0%
PA	0	1	0.0%
SUBTOTAL EXCL F	25,544	33,610	43.2%
PART E	19,069	30,396	38.6%
TOTAL	44,613	64,006	41.1%

Table 6

Percentage of Cases FAB Accept

	FAB Accept	FAB Deny	Percent FAB Accept
	6,378	365	94.6%
	2,079	1,829	53.2%
	93	410	18.5%
	11,094	3,590	75.6%
	5,337	15,457	25.7%
	1,201	915	56.8%
	1	2,951	0.0%
	1	446	0.2%
	0	4,330	0.0%
	2	1,283	0.2%
	0	140	0.0%
	0	1	0.0%
	26,186	31,717	45.2%
	21,159	27,148	43.8%
	47,345	58,865	44.6%

Table 7

Report Qtr Actual Cases Filed By Report Quarter

Report Qtr	PART B										Blank	Subtotal	PART E	TOTAL
	RECA	BD	CS	CN-SEC	CN-NONSEC	BS	OL	RN	OTHER	99				
No Date	2	0	0	1	8	0	0	0	3	0	0	16	5	21
3Q 2001	1,534	825	123	2,363	3,545	188	534	93	666	164	52	10,087	2176	12,263
4Q 2001	348	353	75	1,055	2,848	112	444	77	502	140	47	6,001	2058	8,059
1Q 2002	284	341	43	1,123	2,274	143	356	60	481	149	36	5,290	2823	8,113
2Q 2002	251	253	20	803	1,386	185	252	40	403	101	46	3,740	2413	6,153
3Q 2002	201	140	17	714	995	152	186	34	262	91	37	2,829	2058	4,887
4Q 2002	154	168	17	488	783	90	133	26	198	48	12	2,117	1714	3,831
1Q 2003	106	130	6	530	833	83	134	21	205	44	0	2,092	1604	3,696
2Q 2003	134	125	11	473	836	90	153	17	323	116	2	2,280	2160	4,440
3Q 2003	120	147	13	417	762	71	74	10	134	39	1	1,788	2045	3,833
4Q 2003	155	153	9	433	774	51	66	10	130	40	0	1,821	1826	3,647
1Q 2004	199	198	14	552	865	48	50	7	130	40	1	2,104	1843	3,947
2Q 2004	121	165	7	437	670	44	36	5	85	25	0	1,595	1142	2,737
3Q 2004	139	207	21	524	754	115	47	7	115	22	0	1,951	1336	3,287
4Q 2004	155	89	14	373	505	30	52	5	93	28	0	1,344	1747	3,091
1Q 2005	211	126	14	418	698	56	75	4	80	46	2	1,730	2910	4,640
2Q 2005	273	98	13	437	671	53	53	6	54	17	2	1,677	3685	5,362
3Q 2005	220	79	9	334	593	44	20	2	64	18	2	1,385	2278	3,663
4Q 2005	167	36	8	368	435	27	16	2	25	6	2	1,092	1795	2,887
1Q 2006	185	42	10	355	459	25	17	1	21	6	1	1,122	1710	2,832
2Q 2006	143	34	5	347	408	45	20	1	23	8	5	1,039	1480	2,519
3Q 2006	310	41	8	320	444	44	23	1	23	9	0	1,223	1588	2,811
4Q 2006	222	42	17	358	423	69	33	0	40	19	5	1,228	1639	2,867
1Q 2007	228	49	9	426	703	67	44	2	65	22	0	1,615	2060	3,675
2Q 2007	177	44	7	360	446	42	14	3	32	14	2	1,141	1426	2,567
3Q 2007	123	55	9	389	478	63	11	1	27	11	3	1,170	1429	2,599
4Q 2007	152	40	14	400	458	39	52	4	81	25	1	1,266	1339	2,605
1Q 2008	150	27	6	388	331	41	33	6	41	18	3	1,044	1206	2,250
2Q 2008	136	27	6	495	319	40	32	4	25	17	1	1,102	1363	2,465
3Q 2008	115	24	10	549	378	35	27	2	25	10	2	1,177	1372	2,549
4Q 2008	95	24	5	412	301	24	24	4	24	9	1	923	1153	2,076
1Q 2009	80	27	4	477	436	38	28	4	41	10	1	1,146	1368	2,514
2Q 2009	95	12	3	369	347	35	19	4	19	15	4	922	1106	2,028
3Q 2009	25	2	1	52	60	9	2	0	1	0	34	186	225	411
Total	7,010	4,123	548	17,540	26,226	2,198	3,060	463	4,441	1,327	307	67,243	58,082	125,325

*Third quarter 2009 data is for an incomplete quarter.

Estimation of Part E Average Cost Per case

Benefits Paid to Employee

Impairment Benefits

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than Or Equal To			
0	50,000	2462	60,504,088	24,575
50,000	100,000	1525	111,730,755	73,266
100,000	150,000	1067	133,839,309	125,435
150,000	200,000	556	98,447,079	177,063
200,000	250,000	398	91,216,668	229,188
Total		6008	495,737,899	82,513

Lump Sums

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than Or Equal To			
0	50,000	1	50,000	50,000
50,000	100,000	1	72,500	72,500
100,000	150,000	2	257,500	128,750
150,000	200,000	0	0	0
200,000	250,000	1	207,500	207,500
Total		5	587,500	117,500

Wage Loss Benefits

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than Or Equal To			
0	50,000	145	4,227,625	29,156
50,000	100,000	123	8,781,478	71,394
100,000	150,000	66	8,200,205	124,246
150,000	200,000	30	5,173,845	172,462
200,000	250,000	17	3,958,985	232,881
Total		381	30,342,138	79,638

Additional wage loss benefits may be paid to employees below the normal retirement age.

Total Employee Benefit

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than Or Equal To			
0	50,000	2,430	59,673,914	24,557
50,000	100,000	1,467	107,358,392	73,182
100,000	150,000	1,048	131,411,301	125,392
150,000	200,000	566	100,716,798	177,945
200,000	250,000	546	127,506,925	233,529
Total		6,057	526,667,330	86,952

Maximum Total Benefit, excluding medical, for impairment, wage loss and survivorship is \$250,000.

Benefits Paid to Survivor

Amount of Benefit		Number of Cases	Total Amount Paid	Average Amount Paid
Greater Than	Less Than Or Equal To			
0	50,000	100	2,790,038	27,900
50,000	100,000	241	17,157,612	71,193
100,000	150,000	8,162	1,038,727,870	127,264
150,000	200,000	356	62,314,406	175,040
200,000	250,000	3	720,625	240,208
Total		8,862	1,121,710,551	126,575

Selection of Average Part E Benefit

Employee	60%	\$90,000
Survivor	70%	\$128,000
Average		\$144,000

Selected \$143,000

Assumes 50% of employees that have received awards will die from covered condition and have eligible survivor to receive award.

The employee benefit is selected based on payments to date. Some employees will receive additional wage loss payments but also some claims are accepted for medical payments only with no impairment.

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR RECA CASES**

Exhibit 4

Parameters for fitted curve
m -0.0186 5.4014 b
Starting 3Q 2004
m -0.0389 5.9048 b
Selected Parameters for
m -0.0375 5.7000 b

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12)
Quarter Filed	Year	t	Number of Cases	Judgmental Adjustment	y	ln(y)	Selected Approval Rate	Estimated Approved Cases	Case Amount	Estimated Ultimate Compensation	Approved Cases By Fiscal Year	
3	2001		1,536 Actual	0	1536	7.33694	0.95	1459	50,000	72,950,000	1,459	
4	2001	1	348 Actual	0	348	5.85220	0.95	331	50,000	16,550,000	0	
1	2002	2	284 Actual	0	284	5.64897	0.95	270	50,000	13,500,000	0	
2	2002	3	251 Actual	0	251	5.52545	0.95	238	50,000	11,900,000	0	
3	2002	4	201 Actual	0	201	5.30330	0.95	191	50,000	9,550,000	1,030	
4	2002	5	154 Actual	0	154	5.03695	0.95	146	50,000	7,300,000	0	
1	2003	6	106 Actual	0	106	4.66344	0.95	101	50,000	5,050,000	0	
2	2003	7	134 Actual	0	134	4.89784	0.95	127	50,000	6,350,000	0	
3	2003	8	120 Actual	0	120	4.78749	0.95	114	50,000	5,700,000	488	
4	2003	9	155 Actual	0	155	5.04343	0.95	147	50,000	7,350,000	0	
1	2004	10	199 Actual	0	199	5.29330	0.95	189	50,000	9,450,000	0	
2	2004	11	121 Actual	0	121	4.79579	0.95	115	50,000	5,750,000	0	
3	2004	12	139 Actual	0	139	4.93447	0.95	132	50,000	6,600,000	583	
4	2004	13	155 Actual	0	155	5.04343	0.95	147	50,000	7,350,000	0	
1	2005	14	211 Actual	0	211	5.35186	0.95	200	50,000	10,000,000	0	
2	2005	15	273 Actual	0	273	5.60947	0.95	259	50,000	12,950,000	0	
3	2005	16	220 Actual	0	220	5.39363	0.95	209	50,000	10,450,000	815	
4	2005	17	167 Actual	0	167	5.11799	0.95	159	100,000	15,900,000	0	
1	2006	18	185 Actual	0	185	5.22036	0.95	176	100,000	17,600,000	0	
2	2006	19	143 Actual	0	143	4.96284	0.95	136	100,000	13,600,000	0	
3	2006	20	310 Actual	0	310	5.73657	0.95	295	150,000	44,250,000	766	
4	2006	21	222 Actual	0	222	5.40268	0.95	211	150,000	31,650,000	0	
1	2007	22	228 Actual	0	228	5.42935	0.95	217	150,000	32,550,000	0	
2	2007	23	177 Actual	0	177	5.17615	0.95	168	150,000	25,200,000	0	
3	2007	24	123 Actual	0	123	4.81218	0.95	117	150,000	17,550,000	713	
4	2007	25	152 Actual	0	152	5.02388	0.95	144	150,000	21,600,000	0	
1	2008	26	150 Actual	0	150	5.01064	0.95	143	150,000	21,450,000	0	
2	2008	27	136 Actual	0	136	4.91265	0.95	129	150,000	19,350,000	0	
3	2008	28	115 Actual	0	115	4.74493	0.95	109	150,000	16,350,000	525	
4	2008	29	95 Actual	0	95	4.55388	0.95	90	150,000	13,500,000	0	
1	2009	30	80 Actual	0	80	4.38203	0.95	76	150,000	11,400,000	0	
2	2009	31	95 Actual	0	95	4.55388	0.95	90	150,000	13,500,000	0	
3	2009	32	90 Projected				0.95	86	150,000	12,900,000	342	
4	2009	33	87 Projected				0.95	83	150,000	12,450,000	0	
1	2010	34	84 Projected				0.95	80	150,000	12,000,000	0	
2	2010	35	80 Projected				0.95	76	150,000	11,400,000	0	
3	2010	36	77 Projected				0.95	73	150,000	10,950,000	312	
4	2010	37	75 Projected				0.95	71	150,000	10,650,000	0	
1	2011	38	72 Projected				0.95	68	150,000	10,200,000	0	
2	2011	39	69 Projected				0.95	66	150,000	9,900,000	0	
3	2011	40	67 Projected				0.95	64	150,000	9,600,000	269	
4	2011	41	64 Projected				0.95	61	150,000	9,150,000	0	
1	2012	42	62 Projected				0.95	59	150,000	8,850,000	0	
2	2012	43	60 Projected				0.95	57	150,000	8,550,000	0	
3	2012	44	57 Projected				0.95	54	150,000	8,100,000	231	
4	2012	45	55 Projected				0.95	52	150,000	7,800,000	0	
1	2013	46	53 Projected				0.95	50	150,000	7,500,000	0	
2	2013	47	51 Projected				0.95	48	150,000	7,200,000	0	
3	2013	48	49 Projected				0.95	47	150,000	7,050,000	197	
4	2013	49	48 Projected				0.95	46	150,000	6,900,000	0	
1	2014	50	46 Projected				0.95	44	150,000	6,600,000	0	
2	2014	51	44 Projected				0.95	42	150,000	6,300,000	0	
3	2014	52	43 Projected				0.95	41	150,000	6,150,000	173	
4	2014	53	41 Projected				0.95	39	150,000	5,850,000	0	
1	2015	54	39 Projected				0.95	37	150,000	5,550,000	0	
2	2015	55	38 Projected				0.95	36	150,000	5,400,000	0	
3	2015	56	37 Projected				0.95	35	150,000	5,250,000	147	
4	2015	57	35 Projected				0.95	33	150,000	4,950,000	0	
1	2016	58	34 Projected				0.95	32	150,000	4,800,000	0	
2	2016	59	33 Projected				0.95	31	150,000	4,650,000	0	
3	2016	60	32 Projected				0.95	30	150,000	4,500,000	126	
4	2016	61	30 Projected				0.95	29	150,000	4,350,000	0	
1	2017	62	29 Projected				0.95	28	150,000	4,200,000	0	
2	2017	63	28 Projected				0.95	27	150,000	4,050,000	0	
3	2017	64	27 Projected				0.95	26	150,000	3,900,000	110	
4	2017	65	26 Projected				0.95	25	150,000	3,750,000	0	
1	2018	66	25 Projected				0.95	24	150,000	3,600,000	0	
2	2018	67	24 Projected				0.95	23	150,000	3,450,000	0	
3	2018	68	23 Projected				0.95	22	150,000	3,300,000	94	
4	2018	69	22 Projected				0.95	21	150,000	3,150,000	0	
1	2019	70	22 Projected				0.95	21	150,000	3,150,000	0	
2	2019	71	21 Projected				0.95	20	150,000	3,000,000	0	
3	2019	72	20 Projected				0.95	19	150,000	2,850,000	81	
4	2019	73	19 Projected				0.95	18	150,000	2,700,000	0	
1	2020	74	19 Projected				0.95	18	150,000	2,700,000	0	
2	2020	75	18 Projected				0.95	17	150,000	2,550,000	0	
3	2020	76	17 Projected				0.95	16	150,000	2,400,000	69	
4	2020	77	17 Projected				0.95	16	150,000	2,400,000	0	
1	2021	78	16 Projected				0.95	15	150,000	2,250,000	0	
2	2021	79	15 Projected				0.95	14	150,000	2,100,000	0	
3	2021	80	15 Projected				0.95	14	150,000	2,100,000	59	

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR RECA CASES**

Exhibit 4

Parameters for fitted curve
 m -0.0186 5.4014 b
 Starting 3Q 2004
 m -0.0389 5.9048 b
 Selected Parameters for
 m -0.0375 5.7000 b

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) =(4) x (8)	(10)	(11) =(9) x (10)	(12)
Quarter Filed	Year	t	Number of Cases	Projected	Judgmental Adjustment	y	ln(y)	Selected Approval Rate	Estimated Approved Cases	Case Amount	Estimated Ultimate Compensation	Approved Cases By Fiscal Year
4	2021	81	14	Projected				0.95	13	150,000	1,950,000	0
1	2022	82	14	Projected				0.95	13	150,000	1,950,000	0
2	2022	83	13	Projected				0.95	12	150,000	1,800,000	0
3	2022	84	13	Projected				0.95	12	150,000	1,800,000	50
4	2022	85	12	Projected				0.95	11	150,000	1,650,000	0
1	2023	86	12	Projected				0.95	11	150,000	1,650,000	0
2	2023	87	11	Projected				0.95	10	150,000	1,500,000	0
3	2023	88	11	Projected				0.95	10	150,000	1,500,000	42
4	2023	89	11	Projected				0.95	10	150,000	1,500,000	0
1	2024	90	10	Projected				0.95	10	150,000	1,500,000	0
2	2024	91	10	Projected				0.95	10	150,000	1,500,000	0
3	2024	92	9	Projected				0.95	9	150,000	1,350,000	39
4	2024	93	9	Projected				0.95	9	150,000	1,350,000	0
1	2025	94	9	Projected				0.95	9	150,000	1,350,000	0
2	2025	95	8	Projected				0.95	8	150,000	1,200,000	0
3	2025	96	8	Projected				0.95	8	150,000	1,200,000	34
4	2025	97	8	Projected				0.95	8	150,000	1,200,000	0
1	2026	98	8	Projected				0.95	8	150,000	1,200,000	0
2	2026	99	7	Projected				0.95	7	150,000	1,050,000	0
3	2026	100	7	Projected				0.95	7	150,000	1,050,000	30
4	2026	101	7	Projected				0.95	7	150,000	1,050,000	0
1	2027	102	7	Projected				0.95	7	150,000	1,050,000	0
2	2027	103	6	Projected				0.95	6	150,000	900,000	0
3	2027	104	6	Projected				0.95	6	150,000	900,000	26
4	2027	105	6	Projected				0.95	6	150,000	900,000	0
1	2028	106	6	Projected				0.95	6	150,000	900,000	0
2	2028	107	5	Projected				0.95	5	150,000	750,000	0
3	2028	108	5	Projected				0.95	5	150,000	750,000	22
4	2028	109	5	Projected				0.95	5	150,000	750,000	0
1	2029	110	5	Projected				0.95	5	150,000	750,000	0
2	2029	111	5	Projected				0.95	5	150,000	750,000	0
3	2029	112	4	Projected				0.95	4	150,000	600,000	19
4	2029	113	4	Projected				0.95	4	150,000	600,000	0
1	2030	114	4	Projected				0.95	4	150,000	600,000	0
2	2030	115	4	Projected				0.95	4	150,000	600,000	0
3	2030	116	4	Projected				0.95	4	150,000	600,000	16
			9,327						8,867		869,000,000	8,867

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve
 Column (8) is from Exhibit 1 Page 2 Table 2
 Column (12) is the sum of column (9) for rows in the fiscal year

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR BERYLLIUM DISEASE CASES**

Exhibit 4

Parameters for fitted curve
m -0.0892 5.7472 b
Starting 3Q 2004
m -0.0906 5.7747 b
Parameters Selected for
m -0.0892 5.7472 b

CASES BY QUARTER

Quarter Filed	Year	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
							= (3) + (5)			= (4) x (8)		= (9) x (10)	Approved Cases By Fiscal Year
		t	Number of Cases	Judgmental Adjustment	y	ln(y)		Selected Approval Rate	Approved Cases	Case Amount	Estimated Ultimate Compensation		
3	2001		825 Actual	0	825	6.71538		0.53	437	150,000	65,550,000		437
4	2001	1	353 Actual	0	353	5.86647		0.53	187	150,000	28,050,000		0
1	2002	2	341 Actual	0	341	5.83188		0.53	181	150,000	27,150,000		0
2	2002	3	253 Actual	0	253	5.53339		0.53	134	150,000	20,100,000		0
3	2002	4	140 Actual	0	140	4.94164		0.53	74	150,000	11,100,000		576
4	2002	5	168 Actual	0	168	5.12396		0.53	89	150,000	13,350,000		0
1	2003	6	130 Actual	0	130	4.86753		0.53	69	150,000	10,350,000		0
2	2003	7	125 Actual	0	125	4.82831		0.53	66	150,000	9,900,000		0
3	2003	8	147 Actual	0	147	4.99043		0.53	78	150,000	11,700,000		302
4	2003	9	153 Actual	0	153	5.03044		0.53	81	150,000	12,150,000		0
1	2004	10	198 Actual	0	198	5.28827		0.53	105	150,000	15,750,000		0
2	2004	11	165 Actual	0	165	5.10595		0.53	87	150,000	13,050,000		0
3	2004	12	207 Actual	0	207	5.33272		0.53	110	150,000	16,500,000		383
4	2004	13	89 Actual	0	89	4.48864		0.53	47	150,000	7,050,000		0
1	2005	14	126 Actual	0	126	4.83628		0.53	67	150,000	10,050,000		0
2	2005	15	98 Actual	0	98	4.58497		0.53	52	150,000	7,800,000		0
3	2005	16	79 Actual	0	79	4.36945		0.53	42	150,000	6,300,000		208
4	2005	17	36 Actual	0	36	3.58352		0.53	19	150,000	2,850,000		0
1	2006	18	42 Actual	0	42	3.73767		0.53	22	150,000	3,300,000		0
2	2006	19	34 Actual	0	34	3.52636		0.53	18	150,000	2,700,000		0
3	2006	20	41 Actual	0	41	3.71357		0.53	22	150,000	3,300,000		81
4	2006	21	42 Actual	0	42	3.73767		0.53	22	150,000	3,300,000		0
1	2007	22	49 Actual	0	49	3.89182		0.53	26	150,000	3,900,000		0
2	2007	23	44 Actual	0	44	3.78419		0.53	23	150,000	3,450,000		0
3	2007	24	55 Actual	0	55	4.00733		0.53	29	150,000	4,350,000		100
4	2007	25	40 Actual	0	40	3.68888		0.53	21	150,000	3,150,000		0
1	2008	26	27 Actual	0	27	3.29584		0.53	14	150,000	2,100,000		0
2	2008	27	27 Actual	0	27	3.29584		0.53	14	150,000	2,100,000		0
3	2008	28	24 Actual	1	25	3.21888		0.53	13	150,000	1,950,000		62
4	2008	29	24 Actual	2	26	3.25810		0.53	13	150,000	1,950,000		0
1	2009	30	27 Actual	3	30	3.40120		0.53	14	150,000	2,100,000		0
2	2009	31	12 Actual	4	16	2.77259		0.53	6	150,000	900,000		0
3	2009	32	18 Projected					0.53	10	150,000	1,500,000		43
4	2009	33	17 Projected					0.53	9	150,000	1,350,000		0
1	2010	34	15 Projected					0.53	8	150,000	1,200,000		0
2	2010	35	14 Projected					0.53	7	150,000	1,050,000		0
3	2010	36	13 Projected					0.53	7	150,000	1,050,000		31
4	2010	37	12 Projected					0.53	6	150,000	900,000		0
1	2011	38	11 Projected					0.53	6	150,000	900,000		0
2	2011	39	10 Projected					0.53	5	150,000	750,000		0
3	2011	40	9 Projected					0.53	5	150,000	750,000		22
4	2011	41	8 Projected					0.53	4	150,000	600,000		0
1	2012	42	7 Projected					0.53	4	150,000	600,000		0
2	2012	43	7 Projected					0.53	4	150,000	600,000		0
3	2012	44	6 Projected					0.53	3	150,000	450,000		15
4	2012	45	6 Projected					0.53	3	150,000	450,000		0
1	2013	46	5 Projected					0.53	3	150,000	450,000		0
2	2013	47	5 Projected					0.53	3	150,000	450,000		0
3	2013	48	4 Projected					0.53	2	150,000	300,000		11
4	2013	49	4 Projected					0.53	2	150,000	300,000		0
1	2014	50	4 Projected					0.53	2	150,000	300,000		0
2	2014	51	3 Projected					0.53	2	150,000	300,000		0
3	2014	52	3 Projected					0.53	2	150,000	300,000		8
4	2014	53	3 Projected					0.53	2	150,000	300,000		0
1	2015	54	3 Projected					0.53	2	150,000	300,000		0
2	2015	55	2 Projected					0.53	1	150,000	150,000		0
3	2015	56	2 Projected					0.53	1	150,000	150,000		6
4	2015	57	2 Projected					0.53	1	150,000	150,000		0
1	2016	58	2 Projected					0.53	1	150,000	150,000		0
2	2016	59	2 Projected					0.53	1	150,000	150,000		0
3	2016	60	1 Projected					0.53	1	150,000	150,000		4
4	2016	61	1 Projected					0.53	1	150,000	150,000		0
1	2017	62	1 Projected					0.53	1	150,000	150,000		0
2	2017	63	1 Projected					0.53	1	150,000	150,000		0
3	2017	64	1 Projected					0.53	1	150,000	150,000		4
4	2017	65	1 Projected					0.53	1	150,000	150,000		0
1	2018	66	1 Projected					0.53	1	150,000	150,000		0
2	2018	67	1 Projected					0.53	1	150,000	150,000		0
3	2018	68	1 Projected					0.53	1	150,000	150,000		4
4	2018	69	1 Projected					0.53	1	150,000	150,000		0
1	2019	70	1 Projected					0.53	1	150,000	150,000		0

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR BERYLLIUM DISEASE CASES**

Exhibit 4

Parameters for fitted curve
m -0.0892 5.7472 b
Starting 3Q 2004
m -0.0906 5.7747 b
Parameters Selected for
m -0.0892 5.7472 b

CASES BY QUARTER

Quarter Filed	Year	(1) t	(2) Number of Cases	(3) Judgmental Adjustment	(4) y	(5) ln(y)	(6) = (3) + (5)	(7) ln(y)	(8) Selected Approval Rate	(9) Approved Cases	(10) Case Amount	(11) Estimated Ultimate Compensation	(12) Approved Cases By Fiscal Year
2	2019	71	1	Projected					0.53	1	150,000	150,000	0
3	2019	72	1	Projected					0.53	1	150,000	150,000	4
4	2019	73	0	Projected					0.53	0	150,000	0	0
1	2020	74	0	Projected					0.53	0	150,000	0	0
2	2020	75	0	Projected					0.53	0	150,000	0	0
3	2020	76	0	Projected					0.53	0	150,000	0	0
4	2020	77	0	Projected					0.53	0	150,000	0	0
1	2021	78	0	Projected					0.53	0	150,000	0	0
2	2021	79	0	Projected					0.53	0	150,000	0	0
3	2021	80	0	Projected					0.53	0	150,000	0	0
4	2021	81	0	Projected					0.53	0	150,000	0	0
1	2022	82	0	Projected					0.53	0	150,000	0	0
2	2022	83	0	Projected					0.53	0	150,000	0	0
3	2022	84	0	Projected					0.53	0	150,000	0	0
4	2022	85	0	Projected					0.53	0	150,000	0	0
1	2023	86	0	Projected					0.53	0	150,000	0	0
2	2023	87	0	Projected					0.53	0	150,000	0	0
3	2023	88	0	Projected					0.53	0	150,000	0	0
4	2023	89	0	Projected					0.53	0	150,000	0	0
1	2024	90	0	Projected					0.53	0	150,000	0	0
2	2024	91	0	Projected					0.53	0	150,000	0	0
3	2024	92	0	Projected					0.53	0	150,000	0	0
4	2024	93	0	Projected					0.53	0	150,000	0	0
1	2025	94	0	Projected					0.53	0	150,000	0	0
2	2025	95	0	Projected					0.53	0	150,000	0	0
3	2025	96	0	Projected					0.53	0	150,000	0	0
4	2025	97	0	Projected					0.53	0	150,000	0	0
1	2026	98	0	Projected					0.53	0	150,000	0	0
2	2026	99	0	Projected					0.53	0	150,000	0	0
3	2026	100	0	Projected					0.53	0	150,000	0	0
4	2026	101	0	Projected					0.53	0	150,000	0	0
1	2027	102	0	Projected					0.53	0	150,000	0	0
2	2027	103	0	Projected					0.53	0	150,000	0	0
3	2027	104	0	Projected					0.53	0	150,000	0	0
4	2027	105	0	Projected					0.53	0	150,000	0	0
1	2028	106	0	Projected					0.53	0	150,000	0	0
2	2028	107	0	Projected					0.53	0	150,000	0	0
3	2028	108	0	Projected					0.53	0	150,000	0	0
4	2028	109	0	Projected					0.53	0	150,000	0	0
1	2029	110	0	Projected					0.53	0	150,000	0	0
2	2029	111	0	Projected					0.53	0	150,000	0	0
3	2029	112	0	Projected					0.53	0	150,000	0	0
4	2029	113	0	Projected					0.53	0	150,000	0	0
1	2030	114	0	Projected					0.53	0	150,000	0	0
2	2030	115	0	Projected					0.53	0	150,000	0	0
3	2030	116	0	Projected					0.53	0	150,000	0	0
			4,331							2,301		345,150,000	2,301

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve
 Column (8) is from Exhibit 1 Page 2 Table 2
 Column (12) is the sum of column (9) for rows in the fiscal year

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR CHRONIC SILICOSIS CASES**

Exhibit 4

Parameters for fitted curve
 m -0.0404 3.0677 b
 Starting 3Q 2004
 m -0.0361 3.0156 b
 Parameters Selected for
 m -0.0404 3.0677 b

CASES BY QUARTER

Quarter Filed	Year	(1) t	(2) Number of Cases	(3) Actual	(4) Judgmental Adjustment	(5) y	(6) ln(y) = (3) + (5)	(7) -8.00	(8) Selected Approval Rate	(9) Approved Cases =(4) x (8)	(10) Case Amount	(11) Estimated Ultimate Compensation =(9) x (10)	(12) Approved Cases By Fiscal Year
3	2001		123	Actual	0	123	4.81218	0.18	22	150,000	3,300,000	22	
4	2001	1	75	Actual	0	75	4.31749	0.18	14	150,000	2,100,000	0	
1	2002	2	43	Actual	0	43	3.76120	0.18	8	150,000	1,200,000	0	
2	2002	3	20	Actual	0	20	2.99573	0.18	4	150,000	600,000	0	
3	2002	4	17	Actual	0	17	2.83321	0.18	3	150,000	450,000	29	
4	2002	5	17	Actual	0	17	2.83321	0.18	3	150,000	450,000	0	
1	2003	6	6	Actual	0	6	1.79176	0.18	1	150,000	150,000	0	
2	2003	7	11	Actual	0	11	2.39790	0.18	2	150,000	300,000	0	
3	2003	8	13	Actual	0	13	2.56495	0.18	2	150,000	300,000	8	
4	2003	9	9	Actual	0	9	2.19722	0.18	2	150,000	300,000	0	
1	2004	10	14	Actual	0	14	2.63906	0.18	3	150,000	450,000	0	
2	2004	11	7	Actual	0	7	1.94591	0.18	1	150,000	150,000	0	
3	2004	12	21	Actual	0	21	3.04452	0.18	4	150,000	600,000	10	
4	2004	13	14	Actual	0	14	2.63906	0.18	3	150,000	450,000	0	
1	2005	14	14	Actual	0	14	2.63906	0.18	3	150,000	450,000	0	
2	2005	15	13	Actual	0	13	2.56495	0.18	2	150,000	300,000	0	
3	2005	16	9	Actual	0	9	2.19722	0.18	2	150,000	300,000	10	
4	2005	17	8	Actual	0	8	2.07944	0.18	1	150,000	150,000	0	
1	2006	18	10	Actual	0	10	2.30259	0.18	2	150,000	300,000	0	
2	2006	19	5	Actual	0	5	1.60944	0.18	1	150,000	150,000	0	
3	2006	20	8	Actual	0	8	2.07944	0.18	1	150,000	150,000	5	
4	2006	21	17	Actual	0	17	2.83321	0.18	3	150,000	450,000	0	
1	2007	22	9	Actual	0	9	2.19722	0.18	2	150,000	300,000	0	
2	2007	23	7	Actual	0	7	1.94591	0.18	1	150,000	150,000	0	
3	2007	24	9	Actual	0	9	2.19722	0.18	2	150,000	300,000	8	
4	2007	25	14	Actual	0	14	2.63906	0.18	3	150,000	450,000	0	
1	2008	26	6	Actual	0	6	1.79176	0.18	1	150,000	150,000	0	
2	2008	27	6	Actual	0	6	1.79176	0.18	1	150,000	150,000	0	
3	2008	28	10	Actual	1	11	2.39790	0.18	2	150,000	300,000	7	
4	2008	29	5	Actual	2	7	1.94591	0.18	1	150,000	150,000	0	
1	2009	30	4	Actual	3	7	1.94591	0.18	1	150,000	150,000	0	
2	2009	31	3	Actual	4	7	1.94591	0.18	1	150,000	150,000	0	
3	2009	32	6	Projected				0.18	1	150,000	150,000	4	
4	2009	33	6	Projected				0.18	1	150,000	150,000	0	
1	2010	34	5	Projected				0.18	1	150,000	150,000	0	
2	2010	35	5	Projected				0.18	1	150,000	150,000	0	
3	2010	36	5	Projected				0.18	1	150,000	150,000	4	
4	2010	37	5	Projected				0.18	1	150,000	150,000	0	
1	2011	38	5	Projected				0.18	1	150,000	150,000	0	
2	2011	39	4	Projected				0.18	1	150,000	150,000	0	
3	2011	40	4	Projected				0.18	1	150,000	150,000	4	
4	2011	41	4	Projected				0.18	1	150,000	150,000	0	
1	2012	42	4	Projected				0.18	1	150,000	150,000	0	
2	2012	43	4	Projected				0.18	1	150,000	150,000	0	
3	2012	44	4	Projected				0.18	1	150,000	150,000	4	
4	2012	45	3	Projected				0.18	1	150,000	150,000	0	
1	2013	46	3	Projected				0.18	1	150,000	150,000	0	
2	2013	47	3	Projected				0.18	1	150,000	150,000	0	
3	2013	48	3	Projected				0.18	1	150,000	150,000	4	
4	2013	49	3	Projected				0.18	1	150,000	150,000	0	
1	2014	50	3	Projected				0.18	1	150,000	150,000	0	
2	2014	51	3	Projected				0.18	1	150,000	150,000	0	
3	2014	52	3	Projected				0.18	1	150,000	150,000	4	
4	2014	53	3	Projected				0.18	1	150,000	150,000	0	
1	2015	54	2	Projected				0.18	0	150,000	0	0	
2	2015	55	2	Projected				0.18	0	150,000	0	0	
3	2015	56	2	Projected				0.18	0	150,000	0	1	
4	2015	57	2	Projected				0.18	0	150,000	0	0	
1	2016	58	2	Projected				0.18	0	150,000	0	0	
2	2016	59	2	Projected				0.18	0	150,000	0	0	
3	2016	60	2	Projected				0.18	0	150,000	0	0	
4	2016	61	2	Projected				0.18	0	150,000	0	0	
1	2017	62	2	Projected				0.18	0	150,000	0	0	
2	2017	63	2	Projected				0.18	0	150,000	0	0	
3	2017	64	2	Projected				0.18	0	150,000	0	0	
4	2017	65	2	Projected				0.18	0	150,000	0	0	
1	2018	66	1	Projected				0.18	0	150,000	0	0	
2	2018	67	1	Projected				0.18	0	150,000	0	0	
3	2018	68	1	Projected				0.18	0	150,000	0	0	
4	2018	69	1	Projected				0.18	0	150,000	0	0	
1	2019	70	1	Projected				0.18	0	150,000	0	0	

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR CHRONIC SILICOSIS CASES**

Exhibit 4

Parameters for fitted curve
 m -0.0404 3.0677 b
 Starting 3Q 2004
 m -0.0361 3.0156 b
 Parameters Selected for
 m -0.0404 3.0677 b

CASES BY QUARTER

Quarter Filed	Year	(1) t	(2) Number of Cases	(3) 1 Projected	(4) Judgmental Adjustment	(5) y	(6) ln(y) = (3) + (5)	(7) -8.00	(8) Selected Approval Rate	(9) Approved Cases =(4) x (8)	(10) Case Amount	(11) Estimated Ultimate Compensation =(9) x (10)	(12) Approved Cases By Fiscal Year
2	2019	71	1 Projected					0.18	0	150,000	0	0	
3	2019	72	1 Projected					0.18	0	150,000	0	0	
4	2019	73	1 Projected					0.18	0	150,000	0	0	
1	2020	74	1 Projected					0.18	0	150,000	0	0	
2	2020	75	1 Projected					0.18	0	150,000	0	0	
3	2020	76	1 Projected					0.18	0	150,000	0	0	
4	2020	77	1 Projected					0.18	0	150,000	0	0	
1	2021	78	1 Projected					0.18	0	150,000	0	0	
2	2021	79	1 Projected					0.18	0	150,000	0	0	
3	2021	80	1 Projected					0.18	0	150,000	0	0	
4	2021	81	1 Projected					0.18	0	150,000	0	0	
1	2022	82	1 Projected					0.18	0	150,000	0	0	
2	2022	83	1 Projected					0.18	0	150,000	0	0	
3	2022	84	1 Projected					0.18	0	150,000	0	0	
4	2022	85	1 Projected					0.18	0	150,000	0	0	
1	2023	86	1 Projected					0.18	0	150,000	0	0	
2	2023	87	1 Projected					0.18	0	150,000	0	0	
3	2023	88	1 Projected					0.18	0	150,000	0	0	
4	2023	89	1 Projected					0.18	0	150,000	0	0	
1	2024	90	1 Projected					0.18	0	150,000	0	0	
2	2024	91	1 Projected					0.18	0	150,000	0	0	
3	2024	92	1 Projected					0.18	0	150,000	0	0	
4	2024	93	1 Projected					0.18	0	150,000	0	0	
1	2025	94	0 Projected					0.18	0	150,000	0	0	
2	2025	95	0 Projected					0.18	0	150,000	0	0	
3	2025	96	0 Projected					0.18	0	150,000	0	0	
4	2025	97	0 Projected					0.18	0	150,000	0	0	
1	2026	98	0 Projected					0.18	0	150,000	0	0	
2	2026	99	0 Projected					0.18	0	150,000	0	0	
3	2026	100	0 Projected					0.18	0	150,000	0	0	
4	2026	101	0 Projected					0.18	0	150,000	0	0	
1	2027	102	0 Projected					0.18	0	150,000	0	0	
2	2027	103	0 Projected					0.18	0	150,000	0	0	
3	2027	104	0 Projected					0.18	0	150,000	0	0	
4	2027	105	0 Projected					0.18	0	150,000	0	0	
1	2028	106	0 Projected					0.18	0	150,000	0	0	
2	2028	107	0 Projected					0.18	0	150,000	0	0	
3	2028	108	0 Projected					0.18	0	150,000	0	0	
4	2028	109	0 Projected					0.18	0	150,000	0	0	
1	2029	110	0 Projected					0.18	0	150,000	0	0	
2	2029	111	0 Projected					0.18	0	150,000	0	0	
3	2029	112	0 Projected					0.18	0	150,000	0	0	
4	2029	113	0 Projected					0.18	0	150,000	0	0	
1	2030	114	0 Projected					0.18	0	150,000	0	0	
2	2030	115	0 Projected					0.18	0	150,000	0	0	
3	2030	116	0 Projected					0.18	0	150,000	0	0	
		687								124	18,600,000	124	

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve
 Column (8) is from Exhibit 1 Page 2 Table 2
 Column (12) is the sum of column (9) for rows in the fiscal year

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR CANCER SEC CASES**

Exhibit 4

Parameters for fitted curve
m -0.0205 6.4646 b
Starting 3Q 2004
m 0.0056 5.8742 b
Parameters Selected for
m -0.0225 6.6000 b

CASES BY QUARTER

Quarter Filed	Year	(1) t	(2) Number of Cases	(3) Actual	(4) Judgmental Adjustment	(5) y	(6) = (3) + (5)	(7) ln(y)	(8) Selected Approval Rate	(9) = (4) x (8)	(10) Approved Cases Amount	(11) = (9) x (10)	(12) Estimated Ultimate Compensation	Approved Cases By Fiscal Year
3	2001		2,364	Actual	0	2364	7.76811	0.77	1820	150,000	273,000,000	1,820		
4	2001	1	1,055	Actual	0	1055	6.96130	0.77	812	150,000	121,800,000	0		
1	2002	2	1,123	Actual	0	1123	7.02376	0.77	865	150,000	129,750,000	0		
2	2002	3	803	Actual	0	803	6.68835	0.77	618	150,000	92,700,000	0		
3	2002	4	714	Actual	0	714	6.57088	0.77	550	150,000	82,500,000	2,845		
4	2002	5	488	Actual	0	488	6.19032	0.77	376	150,000	56,400,000	0		
1	2003	6	530	Actual	0	530	6.27288	0.77	408	150,000	61,200,000	0		
2	2003	7	473	Actual	0	473	6.15910	0.77	364	150,000	54,600,000	0		
3	2003	8	417	Actual	0	417	6.03309	0.77	321	150,000	48,150,000	1,469		
4	2003	9	433	Actual	0	433	6.07074	0.77	333	150,000	49,950,000	0		
1	2004	10	552	Actual	0	552	6.31355	0.77	425	150,000	63,750,000	0		
2	2004	11	437	Actual	0	437	6.07993	0.77	336	150,000	50,400,000	0		
3	2004	12	524	Actual	0	524	6.26149	0.77	403	150,000	60,450,000	1,497		
4	2004	13	373	Actual	0	373	5.92158	0.77	287	150,000	43,050,000	0		
1	2005	14	418	Actual	0	418	6.03548	0.77	322	150,000	48,300,000	0		
2	2005	15	437	Actual	0	437	6.07993	0.77	336	150,000	50,400,000	0		
3	2005	16	334	Actual	0	334	5.81114	0.77	257	150,000	38,550,000	1,202		
4	2005	17	368	Actual	0	368	5.90808	0.77	283	150,000	42,450,000	0		
1	2006	18	355	Actual	0	355	5.87212	0.77	273	150,000	40,950,000	0		
2	2006	19	347	Actual	0	347	5.84932	0.77	267	150,000	40,050,000	0		
3	2006	20	320	Actual	0	320	5.76832	0.77	246	150,000	36,900,000	1,069		
4	2006	21	358	Actual	0	358	5.88053	0.77	276	150,000	41,400,000	0		
1	2007	22	426	Actual	0	426	6.05444	0.77	328	150,000	49,200,000	0		
2	2007	23	360	Actual	0	360	5.88610	0.77	277	150,000	41,550,000	0		
3	2007	24	389	Actual	0	389	5.96358	0.77	300	150,000	45,000,000	1,181		
4	2007	25	400	Actual	0	400	5.99146	0.77	308	150,000	46,200,000	0		
1	2008	26	388	Actual	0	388	5.96101	0.77	299	150,000	44,850,000	0		
2	2008	27	495	Actual	0	495	6.20456	0.77	381	150,000	57,150,000	0		
3	2008	28	549	Actual	1	550	6.30992	0.77	423	150,000	63,450,000	1,411		
4	2008	29	412	Actual	2	414	6.02587	0.77	317	150,000	47,550,000	0		
1	2009	30	477	Actual	3	480	6.17379	0.77	367	150,000	55,050,000	0		
2	2009	31	369	Actual	4	373	5.92158	0.77	284	150,000	42,600,000	0		
3	2009	32	358	Projected				0.77	276	150,000	41,400,000	1,244		
4	2009	33	350	Projected				0.77	270	150,000	40,500,000	0		
1	2010	34	342	Projected				0.77	263	150,000	39,450,000	0		
2	2010	35	334	Projected				0.77	257	150,000	38,550,000	0		
3	2010	36	327	Projected				0.77	252	150,000	37,800,000	1,042		
4	2010	37	320	Projected				0.77	246	150,000	36,900,000	0		
1	2011	38	313	Projected				0.77	241	150,000	36,150,000	0		
2	2011	39	306	Projected				0.77	236	150,000	35,400,000	0		
3	2011	40	299	Projected				0.77	230	150,000	34,500,000	953		
4	2011	41	292	Projected				0.77	225	150,000	33,750,000	0		
1	2012	42	286	Projected				0.77	220	150,000	33,000,000	0		
2	2012	43	279	Projected				0.77	215	150,000	32,250,000	0		
3	2012	44	273	Projected				0.77	210	150,000	31,500,000	870		
4	2012	45	267	Projected				0.77	206	150,000	30,900,000	0		
1	2013	46	261	Projected				0.77	201	150,000	30,150,000	0		
2	2013	47	255	Projected				0.77	196	150,000	29,400,000	0		
3	2013	48	250	Projected				0.77	193	150,000	28,950,000	796		
4	2013	49	244	Projected				0.77	188	150,000	28,200,000	0		
1	2014	50	239	Projected				0.77	184	150,000	27,600,000	0		
2	2014	51	233	Projected				0.77	179	150,000	26,850,000	0		
3	2014	52	228	Projected				0.77	176	150,000	26,400,000	727		
4	2014	53	223	Projected				0.77	172	150,000	25,800,000	0		
1	2015	54	218	Projected				0.77	168	150,000	25,200,000	0		
2	2015	55	213	Projected				0.77	164	150,000	24,600,000	0		
3	2015	56	209	Projected				0.77	161	150,000	24,150,000	665		
4	2015	57	204	Projected				0.77	157	150,000	23,550,000	0		
1	2016	58	199	Projected				0.77	153	150,000	22,950,000	0		
2	2016	59	195	Projected				0.77	150	150,000	22,500,000	0		
3	2016	60	191	Projected				0.77	147	150,000	22,050,000	607		
4	2016	61	186	Projected				0.77	143	150,000	21,450,000	0		
1	2017	62	182	Projected				0.77	140	150,000	21,000,000	0		
2	2017	63	178	Projected				0.77	137	150,000	20,550,000	0		
3	2017	64	174	Projected				0.77	134	150,000	20,100,000	554		
4	2017	65	170	Projected				0.77	131	150,000	19,650,000	0		
1	2018	66	167	Projected				0.77	129	150,000	19,350,000	0		
2	2018	67	163	Projected				0.77	126	150,000	18,900,000	0		
3	2018	68	159	Projected				0.77	122	150,000	18,300,000	508		
4	2018	69	156	Projected				0.77	120	150,000	18,000,000	0		
1	2019	70	152	Projected				0.77	117	150,000	17,550,000	0		
2	2019	71	149	Projected				0.77	115	150,000	17,250,000	0		
3	2019	72	145	Projected				0.77	112	150,000	16,800,000	464		

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR CANCER SEC CASES**

Exhibit 4

Parameters for fitted curve
m -0.0205 6.4646 b
Starting 3Q 2004
m 0.0056 5.8742 b
Parameters Selected for
m -0.0225 6.6000 b

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
						= (3) + (5)			= (4) x (8)		= (9) x (10)	
Quarter Filed	Year	Number of Cases		Judgmental Adjustment			ln(y)	Selected Approval Rate	Approved Cases	Case Amount	Estimated Ultimate Compensation	Approved Cases By Fiscal Year
4	2019	73	142	Projected				0.77	109	150,000	16,350,000	0
1	2020	74	139	Projected				0.77	107	150,000	16,050,000	0
2	2020	75	136	Projected				0.77	105	150,000	15,750,000	0
3	2020	76	133	Projected				0.77	102	150,000	15,300,000	423
4	2020	77	130	Projected				0.77	100	150,000	15,000,000	0
1	2021	78	127	Projected				0.77	98	150,000	14,700,000	0
2	2021	79	124	Projected				0.77	95	150,000	14,250,000	0
3	2021	80	122	Projected				0.77	94	150,000	14,100,000	387
4	2021	81	119	Projected				0.77	92	150,000	13,800,000	0
1	2022	82	116	Projected				0.77	89	150,000	13,350,000	0
2	2022	83	114	Projected				0.77	88	150,000	13,200,000	0
3	2022	84	111	Projected				0.77	85	150,000	12,750,000	354
4	2022	85	109	Projected				0.77	84	150,000	12,600,000	0
1	2023	86	106	Projected				0.77	82	150,000	12,300,000	0
2	2023	87	104	Projected				0.77	80	150,000	12,000,000	0
3	2023	88	101	Projected				0.77	78	150,000	11,700,000	324
4	2023	89	99	Projected				0.77	76	150,000	11,400,000	0
1	2024	90	97	Projected				0.77	75	150,000	11,250,000	0
2	2024	91	95	Projected				0.77	73	150,000	10,950,000	0
3	2024	92	93	Projected				0.77	72	150,000	10,800,000	296
4	2024	93	91	Projected				0.77	70	150,000	10,500,000	0
1	2025	94	89	Projected				0.77	69	150,000	10,350,000	0
2	2025	95	87	Projected				0.77	67	150,000	10,050,000	0
3	2025	96	85	Projected				0.77	65	150,000	9,750,000	271
4	2025	97	83	Projected				0.77	64	150,000	9,600,000	0
1	2026	98	81	Projected				0.77	62	150,000	9,300,000	0
2	2026	99	79	Projected				0.77	61	150,000	9,150,000	0
3	2026	100	77	Projected				0.77	59	150,000	8,850,000	246
4	2026	101	76	Projected				0.77	59	150,000	8,850,000	0
1	2027	102	74	Projected				0.77	57	150,000	8,550,000	0
2	2027	103	72	Projected				0.77	55	150,000	8,250,000	0
3	2027	104	71	Projected				0.77	55	150,000	8,250,000	226
4	2027	105	69	Projected				0.77	53	150,000	7,950,000	0
1	2028	106	68	Projected				0.77	52	150,000	7,800,000	0
2	2028	107	66	Projected				0.77	51	150,000	7,650,000	0
3	2028	108	65	Projected				0.77	50	150,000	7,500,000	206
4	2028	109	63	Projected				0.77	49	150,000	7,350,000	0
1	2029	110	62	Projected				0.77	48	150,000	7,200,000	0
2	2029	111	60	Projected				0.77	46	150,000	6,900,000	0
3	2029	112	59	Projected				0.77	45	150,000	6,750,000	188
4	2029	113	58	Projected				0.77	45	150,000	6,750,000	0
1	2030	114	57	Projected				0.77	44	150,000	6,600,000	0
2	2030	115	55	Projected				0.77	42	150,000	6,300,000	0
3	2030	116	54	Projected				0.77	42	150,000	6,300,000	173
			31,195						24,018		3,602,700,000	24,018

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve
Column (8) is from Exhibit 1 Page 2 Table 2
Column (12) is the sum of column (9) for rows in the fiscal year

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR CANCER NON SEC CASES**

Exhibit 4

Parameters for fitted curve
 m -0.0506 7.2373 b
 Starting 3Q 2004
 m -0.0337 6.8631 b
 Parameters Selected for
 m -0.0450 7.2500 b

CASES BY QUARTER

	(1)	(2)	(3)	(4)	(5)	(6)	(7)	-8.00	(9)	(10)	(11)	(12)
						= (3) + (5)			=(4) x (8)		=(9) x (10)	Approved Cases By Fiscal Year
Quarter Filed	Year	t	Number of Cases	Judgmental Adjustment	y	ln(y)	Selected Approval Rate	Approved Cases	Case Amount	Estimated Ultimate Compensation	Approved Cases By Fiscal Year	
3	2001		3,553 Actual	0	3553	8.17555	0.26	924	150,000	138,600,000	924	
4	2001	1	2,848 Actual	0	2848	7.95437	0.26	740	150,000	111,000,000	0	
1	2002	2	2,274 Actual	0	2274	7.72930	0.26	591	150,000	88,650,000	0	
2	2002	3	1,386 Actual	0	1386	7.23418	0.26	360	150,000	54,000,000	0	
3	2002	4	995 Actual	0	995	6.90274	0.26	259	150,000	38,850,000	1,950	
4	2002	5	783 Actual	0	783	6.66313	0.26	204	150,000	30,600,000	0	
1	2003	6	833 Actual	0	833	6.72503	0.26	217	150,000	32,550,000	0	
2	2003	7	836 Actual	0	836	6.72863	0.26	217	150,000	32,550,000	0	
3	2003	8	762 Actual	0	762	6.63595	0.26	198	150,000	29,700,000	836	
4	2003	9	774 Actual	0	774	6.65157	0.26	201	150,000	30,150,000	0	
1	2004	10	865 Actual	0	865	6.76273	0.26	225	150,000	33,750,000	0	
2	2004	11	670 Actual	0	670	6.50728	0.26	174	150,000	26,100,000	0	
3	2004	12	754 Actual	0	754	6.62539	0.26	196	150,000	29,400,000	796	
4	2004	13	505 Actual	0	505	6.22456	0.26	131	150,000	19,650,000	0	
1	2005	14	698 Actual	0	698	6.54822	0.26	181	150,000	27,150,000	0	
2	2005	15	671 Actual	0	671	6.50877	0.26	174	150,000	26,100,000	0	
3	2005	16	593 Actual	0	593	6.38519	0.26	154	150,000	23,100,000	640	
4	2005	17	435 Actual	0	435	6.07535	0.26	113	150,000	16,950,000	0	
1	2006	18	459 Actual	0	459	6.12905	0.26	119	150,000	17,850,000	0	
2	2006	19	408 Actual	0	408	6.01127	0.26	106	150,000	15,900,000	0	
3	2006	20	444 Actual	0	444	6.09582	0.26	115	150,000	17,250,000	453	
4	2006	21	423 Actual	0	423	6.04737	0.26	110	150,000	16,500,000	0	
1	2007	22	703 Actual	0	703	6.55536	0.26	183	150,000	27,450,000	0	
2	2007	23	446 Actual	0	446	6.10032	0.26	116	150,000	17,400,000	0	
3	2007	24	478 Actual	0	478	6.16961	0.26	124	150,000	18,600,000	533	
4	2007	25	458 Actual	0	458	6.12687	0.26	119	150,000	17,850,000	0	
1	2008	26	331 Actual	0	331	5.80212	0.26	86	150,000	12,900,000	0	
2	2008	27	319 Actual	0	319	5.76519	0.26	83	150,000	12,450,000	0	
3	2008	28	378 Actual	1	379	5.93754	0.26	98	150,000	14,700,000	386	
4	2008	29	301 Actual	2	303	5.71373	0.26	78	150,000	11,700,000	0	
1	2009	30	436 Actual	3	439	6.08450	0.26	113	150,000	16,950,000	0	
2	2009	31	347 Actual	4	351	5.86079	0.26	90	150,000	13,500,000	0	
3	2009	32	334 Projected				0.26	87	150,000	13,050,000	368	
4	2009	33	319 Projected				0.26	83	150,000	12,450,000	0	
1	2010	34	305 Projected				0.26	79	150,000	11,850,000	0	
2	2010	35	291 Projected				0.26	76	150,000	11,400,000	0	
3	2010	36	279 Projected				0.26	73	150,000	10,950,000	311	
4	2010	37	266 Projected				0.26	69	150,000	10,350,000	0	
1	2011	38	255 Projected				0.26	66	150,000	9,900,000	0	
2	2011	39	243 Projected				0.26	63	150,000	9,450,000	0	
3	2011	40	233 Projected				0.26	61	150,000	9,150,000	259	
4	2011	41	223 Projected				0.26	58	150,000	8,700,000	0	
1	2012	42	213 Projected				0.26	55	150,000	8,250,000	0	
2	2012	43	203 Projected				0.26	53	150,000	7,950,000	0	
3	2012	44	194 Projected				0.26	50	150,000	7,500,000	216	
4	2012	45	186 Projected				0.26	48	150,000	7,200,000	0	
1	2013	46	178 Projected				0.26	46	150,000	6,900,000	0	
2	2013	47	170 Projected				0.26	44	150,000	6,600,000	0	
3	2013	48	162 Projected				0.26	42	150,000	6,300,000	180	
4	2013	49	155 Projected				0.26	40	150,000	6,000,000	0	
1	2014	50	148 Projected				0.26	38	150,000	5,700,000	0	
2	2014	51	142 Projected				0.26	37	150,000	5,550,000	0	
3	2014	52	136 Projected				0.26	35	150,000	5,250,000	150	
4	2014	53	130 Projected				0.26	34	150,000	5,100,000	0	
1	2015	54	124 Projected				0.26	32	150,000	4,800,000	0	
2	2015	55	119 Projected				0.26	31	150,000	4,650,000	0	
3	2015	56	113 Projected				0.26	29	150,000	4,350,000	126	
4	2015	57	108 Projected				0.26	28	150,000	4,200,000	0	
1	2016	58	104 Projected				0.26	27	150,000	4,050,000	0	
2	2016	59	99 Projected				0.26	26	150,000	3,900,000	0	
3	2016	60	95 Projected				0.26	25	150,000	3,750,000	106	
4	2016	61	90 Projected				0.26	23	150,000	3,450,000	0	
1	2017	62	86 Projected				0.26	22	150,000	3,300,000	0	
2	2017	63	83 Projected				0.26	22	150,000	3,300,000	0	
3	2017	64	79 Projected				0.26	21	150,000	3,150,000	88	
4	2017	65	76 Projected				0.26	20	150,000	3,000,000	0	
1	2018	66	72 Projected				0.26	19	150,000	2,850,000	0	
2	2018	67	69 Projected				0.26	18	150,000	2,700,000	0	
3	2018	68	66 Projected				0.26	17	150,000	2,550,000	74	
4	2018	69	63 Projected				0.26	16	150,000	2,400,000	0	
1	2019	70	60 Projected				0.26	16	150,000	2,400,000	0	
2	2019	71	58 Projected				0.26	15	150,000	2,250,000	0	
3	2019	72	55 Projected				0.26	14	150,000	2,100,000	61	

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR CANCER NON SEC CASES**

Exhibit 4

Parameters for fitted curve
m -0.0506 7.2373 b
Starting 3Q 2004
m -0.0337 6.8631 b
Parameters Selected for
m -0.0450 7.2500 b

CASES BY QUARTER

Quarter Filed	(1) Year	(2) t	(3) Number of Cases	(4) Judgmental Adjustment	(5) y	(6) ln(y)	(7) -8.00	(8) Selected Approval Rate	(9) Approved Cases	(10) Case Amount	(11) Estimated Ultimate Compensation	(12) Approved Cases By Fiscal Year
4	2019	73	53 Projected					0.26	14	150,000	2,100,000	0
1	2020	74	50 Projected					0.26	13	150,000	1,950,000	0
2	2020	75	48 Projected					0.26	12	150,000	1,800,000	0
3	2020	76	46 Projected					0.26	12	150,000	1,800,000	51
4	2020	77	44 Projected					0.26	11	150,000	1,650,000	0
1	2021	78	42 Projected					0.26	11	150,000	1,650,000	0
2	2021	79	40 Projected					0.26	10	150,000	1,500,000	0
3	2021	80	38 Projected					0.26	10	150,000	1,500,000	42
4	2021	81	37 Projected					0.26	10	150,000	1,500,000	0
1	2022	82	35 Projected					0.26	9	150,000	1,350,000	0
2	2022	83	34 Projected					0.26	9	150,000	1,350,000	0
3	2022	84	32 Projected					0.26	8	150,000	1,200,000	36
4	2022	85	31 Projected					0.26	8	150,000	1,200,000	0
1	2023	86	29 Projected					0.26	8	150,000	1,200,000	0
2	2023	87	28 Projected					0.26	7	150,000	1,050,000	0
3	2023	88	27 Projected					0.26	7	150,000	1,050,000	30
4	2023	89	26 Projected					0.26	7	150,000	1,050,000	0
1	2024	90	25 Projected					0.26	7	150,000	1,050,000	0
2	2024	91	23 Projected					0.26	6	150,000	900,000	0
3	2024	92	22 Projected					0.26	6	150,000	900,000	26
4	2024	93	21 Projected					0.26	5	150,000	750,000	0
1	2025	94	20 Projected					0.26	5	150,000	750,000	0
2	2025	95	20 Projected					0.26	5	150,000	750,000	0
3	2025	96	19 Projected					0.26	5	150,000	750,000	20
4	2025	97	18 Projected					0.26	5	150,000	750,000	0
1	2026	98	17 Projected					0.26	4	150,000	600,000	0
2	2026	99	16 Projected					0.26	4	150,000	600,000	0
3	2026	100	16 Projected					0.26	4	150,000	600,000	17
4	2026	101	15 Projected					0.26	4	150,000	600,000	0
1	2027	102	14 Projected					0.26	4	150,000	600,000	0
2	2027	103	14 Projected					0.26	4	150,000	600,000	0
3	2027	104	13 Projected					0.26	3	150,000	450,000	15
4	2027	105	12 Projected					0.26	3	150,000	450,000	0
1	2028	106	12 Projected					0.26	3	150,000	450,000	0
2	2028	107	11 Projected					0.26	3	150,000	450,000	0
3	2028	108	11 Projected					0.26	3	150,000	450,000	12
4	2028	109	10 Projected					0.26	3	150,000	450,000	0
1	2029	110	10 Projected					0.26	3	150,000	450,000	0
2	2029	111	10 Projected					0.26	3	150,000	450,000	0
3	2029	112	9 Projected					0.26	2	150,000	300,000	11
4	2029	113	9 Projected					0.26	2	150,000	300,000	0
1	2030	114	8 Projected					0.26	2	150,000	300,000	0
2	2030	115	8 Projected					0.26	2	150,000	300,000	0
3	2030	116	8 Projected					0.26	2	150,000	300,000	8
			33,581						8,725		1,308,750,000	8,725

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve
Column (8) is from Exhibit 1 Page 2 Table 2
Column (12) is the sum of column (9) for rows in the fiscal year

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR BERYLLIUM SENSITIVITY CASES**

Exhibit 4

Parameters for fitted curve
m -0.0414 4.6886 b
Starting 3Q 2004
m -0.0184 4.1768 b
Parameters Selected for
m -0.0414 4.6886 b

CASES BY QUARTER

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
					= (3) + (5)			= (4) x (8)		= (9) x (10)	
Quarter Filed	Year	Number of Cases	Judgmental Adjustment		y	ln(y)	Selected Approval Rate	Approved Cases	Case Amount	Estimated Ultimate Compensation	Approved Cases By Fiscal Year
3	2001	188 Actual	0	188	5.23644	0.57	107	0	0	107	
4	2001	112 Actual	0	112	4.71850	0.57	64	0	0	0	
1	2002	143 Actual	0	143	4.96284	0.57	82	0	0	0	
2	2002	185 Actual	0	185	5.22036	0.57	105	0	0	0	
3	2002	152 Actual	0	152	5.02388	0.57	87	0	0	338	
4	2002	90 Actual	0	90	4.49981	0.57	51	0	0	0	
1	2003	83 Actual	0	83	4.41884	0.57	47	0	0	0	
2	2003	90 Actual	0	90	4.49981	0.57	51	0	0	0	
3	2003	71 Actual	0	71	4.26268	0.57	40	0	0	189	
4	2003	51 Actual	0	51	3.93183	0.57	29	0	0	0	
1	2004	48 Actual	0	48	3.87120	0.57	27	0	0	0	
2	2004	44 Actual	0	44	3.78419	0.57	25	0	0	0	
3	2004	115 Actual	0	115	4.74493	0.57	66	0	0	147	
4	2004	30 Actual	0	30	3.40120	0.57	17	0	0	0	
1	2005	56 Actual	0	56	4.02535	0.57	32	0	0	0	
2	2005	53 Actual	0	53	3.97029	0.57	30	0	0	0	
3	2005	44 Actual	0	44	3.78419	0.57	25	0	0	104	
4	2005	27 Actual	0	27	3.29584	0.57	15	0	0	0	
1	2006	25 Actual	0	25	3.21888	0.57	14	0	0	0	
2	2006	45 Actual	0	45	3.80666	0.57	26	0	0	0	
3	2006	44 Actual	0	44	3.78419	0.57	25	0	0	80	
4	2006	69 Actual	0	69	4.23411	0.57	39	0	0	0	
1	2007	67 Actual	0	67	4.20469	0.57	38	0	0	0	
2	2007	42 Actual	0	42	3.73767	0.57	24	0	0	0	
3	2007	63 Actual	0	63	4.14313	0.57	36	0	0	137	
4	2007	39 Actual	0	39	3.66356	0.57	22	0	0	0	
1	2008	41 Actual	0	41	3.71357	0.57	23	0	0	0	
2	2008	40 Actual	0	40	3.68888	0.57	23	0	0	0	
3	2008	35 Actual	1	36	3.58352	0.57	20	0	0	88	
4	2008	24 Actual	2	26	3.25810	0.57	14	0	0	0	
1	2009	38 Actual	3	41	3.71357	0.57	22	0	0	0	
2	2009	35 Actual	4	39	3.66356	0.57	20	0	0	0	
3	2009	29 Projected				0.57	17	0	0	73	
4	2009	28 Projected				0.57	16	0	0	0	
1	2010	27 Projected				0.57	15	0	0	0	
2	2010	26 Projected				0.57	15	0	0	0	
3	2010	25 Projected				0.57	14	0	0	60	
4	2010	24 Projected				0.57	14	0	0	0	
1	2011	23 Projected				0.57	13	0	0	0	
2	2011	22 Projected				0.57	13	0	0	0	
3	2011	21 Projected				0.57	12	0	0	52	
4	2011	20 Projected				0.57	11	0	0	0	
1	2012	19 Projected				0.57	11	0	0	0	
2	2012	18 Projected				0.57	10	0	0	0	
3	2012	18 Projected				0.57	10	0	0	42	
4	2012	17 Projected				0.57	10	0	0	0	
1	2013	16 Projected				0.57	9	0	0	0	
2	2013	16 Projected				0.57	9	0	0	0	
3	2013	15 Projected				0.57	9	0	0	37	
4	2013	14 Projected				0.57	8	0	0	0	
1	2014	14 Projected				0.57	8	0	0	0	
2	2014	13 Projected				0.57	7	0	0	0	
3	2014	13 Projected				0.57	7	0	0	30	
4	2014	12 Projected				0.57	7	0	0	0	
1	2015	12 Projected				0.57	7	0	0	0	
2	2015	11 Projected				0.57	6	0	0	0	
3	2015	11 Projected				0.57	6	0	0	26	
4	2015	10 Projected				0.57	6	0	0	0	
1	2016	10 Projected				0.57	6	0	0	0	
2	2016	9 Projected				0.57	5	0	0	0	
3	2016	9 Projected				0.57	5	0	0	22	
4	2016	9 Projected				0.57	5	0	0	0	
1	2017	8 Projected				0.57	5	0	0	0	
2	2017	8 Projected				0.57	5	0	0	0	
3	2017	8 Projected				0.57	5	0	0	20	
4	2017	7 Projected				0.57	4	0	0	0	
1	2018	7 Projected				0.57	4	0	0	0	
2	2018	7 Projected				0.57	4	0	0	0	
3	2018	7 Projected				0.57	4	0	0	16	
4	2018	6 Projected				0.57	3	0	0	0	
1	2019	6 Projected				0.57	3	0	0	0	

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR BERYLLIUM SENSITIVITY CASES**

Exhibit 4

Parameters for fitted curve
 m -0.0414 4.6886 b
 Starting 3Q 2004
 m -0.0184 4.1768 b
 Parameters Selected for
 m -0.0414 4.6886 b

CASES BY QUARTER

Quarter Filed	Year	(1) (2)	(3) Number of Cases	(4) Judgmental Adjustment	(5) y	(6) = (3) + (5)	(7) ln(y)	(8) Selected Approval Rate	(9) Approved Cases	(10) Case Amount	(11) Estimated Ultimate Compensation	(12) Approved Cases By Fiscal Year
2	2019	71	6 Projected					0.57	3	0	0	0
3	2019	72	6 Projected					0.57	3	0	0	12
4	2019	73	5 Projected					0.57	3	0	0	0
1	2020	74	5 Projected					0.57	3	0	0	0
2	2020	75	5 Projected					0.57	3	0	0	0
3	2020	76	5 Projected					0.57	3	0	0	12
4	2020	77	4 Projected					0.57	2	0	0	0
1	2021	78	4 Projected					0.57	2	0	0	0
2	2021	79	4 Projected					0.57	2	0	0	0
3	2021	80	4 Projected					0.57	2	0	0	8
4	2021	81	4 Projected					0.57	2	0	0	0
1	2022	82	4 Projected					0.57	2	0	0	0
2	2022	83	4 Projected					0.57	2	0	0	0
3	2022	84	3 Projected					0.57	2	0	0	8
4	2022	85	3 Projected					0.57	2	0	0	0
1	2023	86	3 Projected					0.57	2	0	0	0
2	2023	87	3 Projected					0.57	2	0	0	0
3	2023	88	3 Projected					0.57	2	0	0	8
4	2023	89	3 Projected					0.57	2	0	0	0
1	2024	90	3 Projected					0.57	2	0	0	0
2	2024	91	3 Projected					0.57	2	0	0	0
3	2024	92	2 Projected					0.57	1	0	0	7
4	2024	93	2 Projected					0.57	1	0	0	0
1	2025	94	2 Projected					0.57	1	0	0	0
2	2025	95	2 Projected					0.57	1	0	0	0
3	2025	96	2 Projected					0.57	1	0	0	4
4	2025	97	2 Projected					0.57	1	0	0	0
1	2026	98	2 Projected					0.57	1	0	0	0
2	2026	99	2 Projected					0.57	1	0	0	0
3	2026	100	2 Projected					0.57	1	0	0	4
4	2026	101	2 Projected					0.57	1	0	0	0
1	2027	102	2 Projected					0.57	1	0	0	0
2	2027	103	2 Projected					0.57	1	0	0	0
3	2027	104	1 Projected					0.57	1	0	0	4
4	2027	105	1 Projected					0.57	1	0	0	0
1	2028	106	1 Projected					0.57	1	0	0	0
2	2028	107	1 Projected					0.57	1	0	0	0
3	2028	108	1 Projected					0.57	1	0	0	4
4	2028	109	1 Projected					0.57	1	0	0	0
1	2029	110	1 Projected					0.57	1	0	0	0
2	2029	111	1 Projected					0.57	1	0	0	0
3	2029	112	1 Projected					0.57	1	0	0	4
4	2029	113	1 Projected					0.57	1	0	0	0
1	2030	114	1 Projected					0.57	1	0	0	0
2	2030	115	1 Projected					0.57	1	0	0	0
3	2030	116	1 Projected					0.57	1	0	0	4
			2,885						1,647		0	1,647

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve
 Column (8) is from Exhibit 1 Page 2 Table 2
 Column (12) is the sum of column (9) for rows in the fiscal year

**PROJECTED APPROVED CASES BY QUARTER FILED
FOR PART E CASES**

Exhibit 4

Parameters for fitted curve
 m -0.0191 7.7354 b
 -0.0344 8.1268 Starting 3Q 2004
 Parameters Selected for
 m -0.0300 8.0000 b

CASES BY QUARTER

Quarter Filed	Year	(1)	(2)	(3)	(4)	(5)	(6) = (3) + (5)	(7)	(8)	(9) = (4) x (8)	(10)	(11) = (9) x (10)	(12)
2	2027	103		136	Projected				0.44	60	143,000	8,580,000	0
3	2027	104		132	Projected				0.44	58	143,000	8,294,000	243
4	2027	105		128	Projected				0.44	56	143,000	8,008,000	0
1	2028	106		124	Projected				0.44	55	143,000	7,865,000	0
2	2028	107		120	Projected				0.44	53	143,000	7,579,000	0
3	2028	108		117	Projected				0.44	51	143,000	7,293,000	215
4	2028	109		113	Projected				0.44	50	143,000	7,150,000	0
1	2029	110		110	Projected				0.44	48	143,000	6,864,000	0
2	2029	111		107	Projected				0.44	47	143,000	6,721,000	0
3	2029	112		104	Projected				0.44	46	143,000	6,578,000	191
4	2029	113		100	Projected				0.44	44	143,000	6,292,000	0
1	2030	114		98	Projected				0.44	43	143,000	6,149,000	0
2	2030	115		95	Projected				0.44	42	143,000	6,006,000	0
3	2030	116		92	Projected				0.44	40	143,000	5,720,000	169
4	2030	116		92	Projected				0.44	40	143,000	5,720,000	0
1	2031	117		89	Projected				0.44	39	143,000	5,577,000	0
2	2031	118		86	Projected				0.44	38	143,000	5,434,000	0
3	2031	119		84	Projected				0.44	37	143,000	5,291,000	154
4	2031	120		81	Projected				0.44	36	143,000	5,148,000	0
1	2032	121		79	Projected				0.44	35	143,000	5,005,000	0
2	2032	122		77	Projected				0.44	34	143,000	4,862,000	0
3	2032	123		74	Projected				0.44	33	143,000	4,719,000	138
4	2032	124		72	Projected				0.44	32	143,000	4,576,000	0
1	2033	125		70	Projected				0.44	31	143,000	4,433,000	0
2	2033	126		68	Projected				0.44	30	143,000	4,290,000	0
3	2033	127		66	Projected				0.44	29	143,000	4,147,000	122
4	2033	128		64	Projected				0.44	28	143,000	4,004,000	0
1	2034	129		62	Projected				0.44	27	143,000	3,861,000	0
2	2034	130		60	Projected				0.44	26	143,000	3,718,000	0
3	2034	131		59	Projected				0.44	26	143,000	3,718,000	107
4	2034	132		57	Projected				0.44	25	143,000	3,575,000	0
1	2035	133		55	Projected				0.44	24	143,000	3,432,000	0
2	2035	134		54	Projected				0.44	24	143,000	3,432,000	0
3	2035	135		52	Projected				0.44	23	143,000	3,289,000	96
4	2035	136		50	Projected				0.44	22	143,000	3,146,000	0
1	2036	137		49	Projected				0.44	22	143,000	3,146,000	0
2	2036	138		47	Projected				0.44	21	143,000	3,003,000	0
3	2036	139		46	Projected				0.44	20	143,000	2,860,000	85
4	2036	140		45	Projected				0.44	20	143,000	2,860,000	0
1	2037	141		43	Projected				0.44	19	143,000	2,717,000	0
2	2037	142		42	Projected				0.44	18	143,000	2,574,000	0
3	2037	143		41	Projected				0.44	18	143,000	2,574,000	75
4	2037	144		40	Projected				0.44	18	143,000	2,574,000	0
1	2038	145		38	Projected				0.44	17	143,000	2,431,000	0
2	2038	146		37	Projected				0.44	16	143,000	2,288,000	0
3	2038	147		36	Projected				0.44	16	143,000	2,288,000	67
4	2038	148		35	Projected				0.44	15	143,000	2,145,000	0
1	2039	149		34	Projected				0.44	15	143,000	2,145,000	0
2	2039	150		33	Projected				0.44	15	143,000	2,145,000	0
3	2039	151		32	Projected				0.44	14	143,000	2,002,000	59
4	2039	152		31	Projected				0.44	14	143,000	2,002,000	0
1	2040	153		30	Projected				0.44	13	143,000	1,859,000	0
2	2040	154		29	Projected				0.44	13	143,000	1,859,000	0
3	2040	155		29	Projected				0.44	13	143,000	1,859,000	53
4	2040	156		28	Projected				0.44	12	143,000	1,716,000	0
1	2041	157		27	Projected				0.44	12	143,000	1,716,000	0
2	2041	158		26	Projected				0.44	11	143,000	1,573,000	0
3	2041	159		25	Projected				0.44	11	143,000	1,573,000	46
4	2041	160		25	Projected				0.44	11	143,000	1,573,000	0
1	2042	161		24	Projected				0.44	11	143,000	1,573,000	0
2	2042	162		23	Projected				0.44	10	143,000	1,430,000	0
3	2042	163		22	Projected				0.44	10	143,000	1,430,000	42
4	2042	164		22	Projected				0.44	10	143,000	1,430,000	0
1	2043	165		21	Projected				0.44	9	143,000	1,287,000	0
2	2043	166		20	Projected				0.44	9	143,000	1,287,000	0
3	2043	167		20	Projected				0.44	9	143,000	1,287,000	37
4	2043	168		19	Projected				0.44	8	143,000	1,144,000	0
1	2044	169		19	Projected				0.44	8	143,000	1,144,000	0
2	2044	170		18	Projected				0.44	8	143,000	1,144,000	0
3	2044	171		18	Projected				0.44	8	143,000	1,144,000	32
4	2044	172		17	Projected				0.44	7	143,000	1,001,000	0
1	2045	173		17	Projected				0.44	7	143,000	1,001,000	0
2	2045	174		16	Projected				0.44	7	143,000	1,001,000	0
3	2045	175		16	Projected				0.44	7	143,000	1,001,000	28

96,051 42,263 6,043,609,000 42,263

Column (3) lines 1-28 are from Exhibit 3 Page 2 Table 7, remaining lines projected using a fitted exponential curve
 Column (8) is from Exhibit 1 Page 2 Table 2
 Column (12) is the sum of column (9) for rows in the fiscal year

Table 1

ESTIMATED CASES BY FISCAL YEAR FILED THAT ARE ULTIMATELY APPROVED UNDER EEOIC

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
Filing Date	RECA	BD	CS	CN - SEC	CN-NON SEC	BS	PART E	TOTAL
7/01-9/01	1,459	437	22	1,820	924	107	960	5,729
10/01-9/02	1,030	576	29	2,845	1,950	338	4,116	10,884
10/02-9/03	488	302	8	1,469	836	189	3,310	6,602
10/03-9/04	583	383	10	1,497	796	147	2,704	6,120
10/04-9/05	815	208	10	1,202	640	104	4,672	7,651
10/05-9/06	766	81	5	1,069	453	80	2,892	5,346
10/06-9/07	713	100	8	1,181	533	137	2,883	5,555
10/07-9/08	525	62	7	1,411	386	88	2,324	4,803
10/08-9/09	342	43	4	1,244	368	73	2,098	4,172
10/09-9/10	312	31	4	1,042	311	60	1,865	3,625
10/10-9/11	269	22	4	953	259	52	1,653	3,212
10/11-9/12	231	15	4	870	216	42	1,466	2,844
10/12-9/13	197	11	4	796	180	37	1,301	2,526
10/13-9/14	173	8	4	727	150	30	1,153	2,245
10/14-9/15	147	6	1	665	126	26	1,025	1,996
10/15-9/16	126	4	0	607	106	22	908	1,773
10/16-9/17	110	4	0	554	88	20	804	1,580
10/17-9/18	94	4	0	508	74	16	715	1,411
10/18-9/19	81	4	0	464	61	12	633	1,255
10/19-9/20	69	0	0	423	51	12	562	1,117
10/20-9/21	59	0	0	387	42	8	498	994
10/21-9/22	50	0	0	354	36	8	442	890
10/22-9/23	42	0	0	324	30	8	392	796
10/23-9/24	39	0	0	296	26	7	347	715
10/24-9/25	34	0	0	271	20	4	308	637
10/25-9/26	30	0	0	246	17	4	273	570
10/26-9/27	26	0	0	226	15	4	243	514
10/27-9/28	22	0	0	206	12	4	215	459
10/28-9/29	19	0	0	188	11	4	191	413
10/29-9/30	16	0	0	173	8	4	169	370
10/30-9/31							154	154
10/31-9/32							138	138
10/32-9/33							122	122
10/33-9/34							107	107
10/34-9/35							96	96
10/35-9/36							85	85
10/36-9/37							75	75
10/37-9/38							67	67
10/38-9/39							59	59
10/39-9/40							53	53
10/40-9/41							46	46
10/41-9/42							42	42
10/42-9/43							37	37
10/43-9/44							32	32
10/44-9/45							28	28
Total	8,867	2,301	124	24,018	8,725	1,647	42,263	87,945

Columns (2) - (8) Data are from Exhibit 4 Column (12) for the respective disease

Table 2

Fiscal Yr Pd	ESTIMATED NUMBER OF PAID CASES BY FISCAL YEAR							BS Claims
	RECA	BD	CS	CN - SEC	CN-NON SEC	PART E	TOTAL	Approved
7/01-9/01	56	1	0	35	0	0	92	0
10/01-9/02	1,778	405	25	1,299	3	0	3,510	137
10/02-9/03	766	392	16	1,240	135	0	2,549	395
10/03-9/04	572	295	5	673	493	0	2,038	108
10/04-9/05	578	234	11	788	968	1,555	4,134	70
10/05-9/06	472	198	6	1,365	1,343	2,176	5,560	62
10/06-9/07	1,023	156	12	1,474	1,137	3,218	7,020	172
10/07-9/08	722	145	7	2,201	706	4,453	8,234	159
10/08-9/09	451	116	9	2,219	487	4,228	7,510	119
10/09-9/10	335	85	8	1,484	600	3,186	5,698	81
10/10-9/11	304	73	8	1,282	451	2,627	4,745	72
10/11-9/12	261	63	4	1,193	433	2,401	4,355	42
10/12-9/13	223	56	4	1,110	376	2,168	3,937	37
10/13-9/14	189	52	4	1,036	324	1,955	3,560	30
10/14-9/15	173	8	4	727	216	1,768	2,896	26
10/15-9/16	147	6	1	665	180	1,603	2,602	22
10/16-9/17	126	4	0	607	150	1,455	2,342	20
10/17-9/18	110	4	0	554	126	1,327	2,121	16
10/18-9/19	94	4	0	508	106	1,210	1,922	12
10/19-9/20	81	4	0	464	88	804	1,441	12
10/20-9/21	69	0	0	423	74	715	1,281	8
10/21-9/22	59	0	0	387	61	633	1,140	8
10/22-9/23	50	0	0	354	51	562	1,017	8
10/23-9/24	42	0	0	324	42	498	906	7
10/24-9/25	39	0	0	296	36	442	813	4
10/25-9/26	34	0	0	271	30	392	727	4
10/26-9/27	30	0	0	246	26	347	649	4
10/27-9/28	26	0	0	226	20	308	580	4
10/28-9/29	22	0	0	206	17	273	518	4
10/29-9/30	19	0	0	188	15	243	465	4
10/30-9/31	16	0	0	173	12	215	416	0
10/31-9/32		0	0	0	11	191	202	0
10/32-9/33					8	169	177	
10/33-9/34					0	154	154	
10/34-9/35						138	138	
10/35-9/36						122	122	
10/36-9/37						107	107	
10/37-9/38						96	96	
10/38-9/39						85	85	
10/39-9/40						75	75	
10/40-9/41						67	67	
10/41-9/42						59	59	
10/42-9/43						53	53	
10/43-9/44						46	46	
10/44-9/45						42	42	
10/45-9/46						37	37	
10/46-9/47						32	32	
10/47-9/48						28	28	
10/48-9/49						0	0	
10/49-9/50								
Total	8,867	2,301	124	24,018	8,725	42,263	86,298	1,647

The first eight rows for each disease are actual data from Exhibit 3 Page 3 Table 9. For 10/08-9/09 the number of claims paid in the last quarter is assumed to be the same as the number paid in the prior quarter. For RECA, the 10/09-9/10 fiscal year is calculated as the number of cases approved from 10/08-9/09 from Table 1 plus a correction term of 1/5 of the difference in the number of cases approved from 7/01 through 9/08 from Table 1 and the number of cases approved from 7/01 through 9/09 from the first eight rows of this table. This is based on an assumption that RECA cases are paid one year after they are filed. The remaining fiscal years are calculated as the number of claims approved in the prior year with fiscal years through 10/13-9/14 containing the correction term.

The remaining Part B diseases are similar with the assumption used is that a case is paid one year after it is filed for BD, CS, CN-SEC and three years for CN-NONSEC. The correction term is spread over 5 years for RECA, BD, CN-SEC and CN-NONSEC. There is no correction term for CS. Part E claims are assumed to be paid 3 years after they are filed (1 year from filing to approval and 2 years duration of payments). The correction term for Part E is spread over 10 years.

The number of BD cases includes BS cases paid and the number of RECA cases includes cases from all other otherwise non-covered diseases.

Table 3

ESTIMATED CASES ELIGIBLE FOR MEDICAL EXPENSES

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
Filing Date	RECA	BD	CS	CN - SEC	CN-NON SEC	BS	PART B NEW MEDICAL	PART E NEW MEDICAL	PART B ONGOING MEDICAL	PART E ONGOING MEDICAL
7/01-9/01	37	0	0	13	0	0	50	0	50	0
10/01-9/02	589	321	15	506	0	137	1,568	0	1,615	0
10/02-9/03	273	234	8	333	23	395	1,266	0	2,793	0
10/03-9/04	303	138	4	199	140	108	892	0	3,529	0
10/04-9/05	380	97	7	227	300	70	1,081	2	4,408	2
10/05-9/06	343	102	6	425	519	62	1,457	121	5,606	123
10/06-9/07	727	70	5	402	450	172	1,826	1,281	7,096	1,397
10/07-9/08	423	85	5	628	276	159	1,576	2,575	8,242	3,896
10/08-9/09	258	77	4	628	231	119	1,317	3,006	9,049	6,686
10/09-9/10	171	47	5	674	282	81	1,260	1,808	9,735	8,117
10/10-9/11	155	40	5	582	212	72	1,066	1,490	10,167	9,137
10/11-9/12	133	35	3	541	203	42	957	1,362	10,443	9,953
10/12-9/13	114	31	3	504	177	37	866	1,230	10,588	10,570
10/13-9/14	97	29	3	470	152	30	781	1,109	10,615	11,007
10/14-9/15	88	4	3	330	101	26	552	1,003	10,388	11,289
10/15-9/16	75	3	1	302	85	22	488	909	10,086	11,433
10/16-9/17	64	2	0	275	70	20	431	825	9,722	11,458
10/17-9/18	56	2	0	251	59	16	384	753	9,313	11,382
10/18-9/19	48	2	0	231	50	12	343	686	8,868	11,216
10/19-9/20	41	2	0	211	41	12	307	456	8,400	10,805
10/20-9/21	35	0	0	192	35	8	270	406	7,910	10,343
10/21-9/22	30	0	0	176	29	8	243	359	7,414	9,840
10/22-9/23	26	0	0	161	24	8	219	319	6,919	9,308
10/23-9/24	21	0	0	147	20	7	195	283	6,427	8,757
10/24-9/25	20	0	0	134	17	4	175	251	5,945	8,196
10/25-9/26	17	0	0	123	14	4	158	222	5,479	7,632
10/26-9/27	15	0	0	112	12	4	143	197	5,030	7,073
10/27-9/28	13	0	0	103	9	4	129	175	4,601	6,526
10/28-9/29	11	0	0	93	8	4	116	155	4,195	5,995
10/29-9/30	10	0	0	85	7	4	106	138	3,813	5,485
10/30-9/31	8	0	0	79	6	0	93	122	3,453	4,998
10/31-9/32		0	0	0	5	0	5	108	3,039	4,535
10/32-9/33					4		4	96	2,663	4,098
10/33-9/34							0	87	2,318	3,690
10/34-9/35								78	2,009	3,311
10/35-9/36								69	1,733	2,961
10/36-9/37								61	1,487	2,640
10/37-9/38								54	1,271	2,347
10/38-9/39								48	1,080	2,083
10/39-9/40								43	913	1,847
10/40-9/41								38	769	1,635
10/41-9/42								33	645	1,445
10/42-9/43								30	538	1,278
10/43-9/44								26	446	1,128
10/44-9/45								24	368	996
10/45-9/46								21	302	879
10/46-9/47								18	246	777
10/47-9/48								16	199	687
10/48-9/49									160	594
10/49-9/50									128	512
10/50-9/51									101	441
10/51-9/52									79	378
10/52-9/53									61	324
10/53-9/54									47	277
10/54-9/55									35	236
10/55-9/56									26	200
10/56-9/57									19	169
10/57-9/58									14	142
10/58-9/59									9	119
10/59-9/60									6	99
Total	4,581	1,321	77	9,137	3,561	1,647	20,324	22,093	232,610	252,452

The first eight rows of the new medical are from Exhibit 3 Table 10. The third quarter 2009 is estimated to be the same as the prior quarter.

For each disease, the number of new cases eligible for medical payments is the estimated number of paid cases from Exhibit 5 Table 1 times the percentage filed by a living employee from Exhibit 1 Page 2 Table 3 times a mortality factor based on the assumption that the percentage of living employees filing claims will decrease over time.

The age at filing a claim is assumed to be 67. The claimants from the prior year are 68 and 2 years prior 69, etc. The probabilities of living an additional year are from Exhibit 1 Table 4.

The ongoing medical is estimated as the new medical plus each prior years new medical with a mortality factor applied.

Part B medical in column (8) is the sum of columns (2) through (7).

Assumes that a claimant is eligible for medical treatment in the same year as the claim is paid.

Assumption Sensitivity Analysis

This exhibit is used to show the impact of varying some of the major assumptions used in the analysis.

		Undiscounted Future Liability			Discounted Future Liability			Percentage Change In Total Discounted Future Liability
		Part B	Part E	Total	Part B	Part E	Total	
Current Assumptions		\$6,681,514,227	\$6,077,121,631	\$12,758,635,858	\$4,208,726,174	\$3,854,836,876	\$8,063,563,050	
Number of Claims Filed								
Current	Selected slope of fitted curve	6,681,514,227	6,077,121,631	12,758,635,858	4,208,726,174	3,854,836,876	8,063,563,050	0.0%
RECA	-0.0375							
BD	-0.0892							
CS	-0.0404							
CN - SEC	-0.0225							
CN - NONSEC	-0.0450							
BS	-0.0414							
PART E	-0.0300							
More claims	Add .01 to slope	10,712,379,473	10,220,237,782	20,932,617,255	6,220,823,931	5,589,947,603	11,810,771,533	46.5%
RECA	-0.0275							
BD	-0.0792							
CS	-0.0304							
CN - SEC	-0.0125							
CN - NONSEC	-0.0350							
BS	-0.0314							
PART E	-0.0200							
Fewer claims	Subtract .01 from slope	4,706,078,888	4,298,823,153	9,004,902,041	3,149,279,846	2,989,657,514	6,138,937,360	-23.9%
RECA	-0.0475							
BD	-0.0992							
CS	-0.0504							
CN - SEC	-0.0325							
CN - NONSEC	-0.0550							
BS	-0.0514							
PART E	-0.0400							
Medical Inflation Rate								
Current	6%	6,681,514,227	6,077,121,631	12,758,635,858	4,208,726,174	3,854,836,876	8,063,563,050	0.0%
	8%	8,046,027,764	7,128,318,874	15,174,346,638	4,724,670,575	4,185,668,787	8,910,339,362	10.5%
	4%	5,759,959,141	5,423,843,958	11,183,803,099	3,832,846,368	3,626,879,750	7,459,726,118	-7.5%
Medical Cost Per Case B and E								
Current - Part B	\$9,540	6,681,514,227	6,077,121,631	12,758,635,858	4,208,726,174	3,854,836,876	8,063,563,050	0.0%
Part E	\$3,800							
10% Higher Part B	\$10,494	7,064,397,218	6,304,009,106	13,368,406,324	4,411,455,795	3,959,613,504	8,371,069,300	3.8%
Part E	\$4,180							
10% Lower Part B	\$8,586	6,298,626,948	5,850,275,843	12,148,902,791	4,005,993,244	3,750,078,550	7,756,071,794	-3.8%
Part E	\$3,420							
Approval Rates								
Current		6,681,514,227	6,077,121,631	12,758,635,858	4,208,726,174	3,854,836,876	8,063,563,050	0.0%
RECA	95%							
BD	53%							
CS	18%							
CN - SEC	77%							
CN - NONSEC	26%							
BS	57%							
PART E	44%							
10% Higher		\$7,816,930,599	\$6,874,920,765	\$14,691,851,364	4,999,523,449	4,383,940,577	9,383,464,026	16.4%
RECA	100%							
BD	58%							
CS	20%							
CN - SEC	85%							
CN - NONSEC	29%							
BS	63%							
PART E	48%							
10% Lower		\$5,441,396,638	\$5,284,265,763	10,725,662,401	\$3,345,350,209	\$3,327,715,799	\$6,673,066,007	-17.2%
RECA	86%							
BD	48%							
CS	16%							
CN - SEC	69%							
CN - NONSEC	23%							
BS	51%							
PART E	40%							
Interest Rate used to Discount Reserves								
Current	4.715%	6,681,514,227	6,077,121,631	12,758,635,858	\$4,208,726,174	\$3,854,836,876	\$8,063,563,050	0.0%
	5.715%	6,681,514,227	6,077,121,631	12,758,635,858	3,896,085,969	3,582,340,899	7,478,426,868	-7.3%
	3.715%	6,681,514,227	6,077,121,631	12,758,635,858	4,577,669,812	4,178,553,244	8,756,223,057	8.6%